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ABSTRACT 
LANCE JOHNSON:  Apolipoprotein E in Diabetic Dyslipidemia and Atherosclerosis 
 (Under the direction of Nobuyo Maeda, PhD) 
 
Each year, cardiovascular disease (CVD) kills more Americans than any other cause of 
death.  The majority of the diseases contributing to CVD can be traced back to the pathological 
process of atherosclerosis, in which fatty material collects along the walls of arteries, limiting 
flexibility and obstructing blood flow.  Plasma lipids, particularly in the form of low-density 
lipoprotein (LDL) cholesterol, contribute significantly to the formation of atherosclerotic 
plaques and are an important determinant of CVD risk.  Thus, it is critical to understand the 
roles of the crucial components of normal lipoprotein metabolism that regulate plasma lipids, 
such as apolipoprotein (apo) B, apoE and the LDL receptor.  In addition, patients with diabetes 
are two to four times as likely to develop CVD as non-diabetic patients.  One important reason 
for this discrepancy is the process of diabetic dyslipidemia – a cluster of harmful changes to 
normal lipoprotein metabolism commonly seen in patients with diabetes.  ApoE is the primary 
ligand for several lipoprotein receptors, making it a crucial component in the clearance of lipid 
from the circulation and a major determinant of plasma cholesterol and cardiovascular disease 
risk.  The APOE gene is polymorphic, resulting in production of three common isoforms: 
ApoE2, E3, and E4.  In addition to its role in lipoprotein metabolism, recent findings have also 
suggested a role for ApoE in glucose metabolism.  In Chapter 2, I examine the role of apoE3 
and apoE4 during the process of diabetic dyslipidemia and atherosclerosis.  Similarly, Chapter 
 iv
3 focuses on the crucial interaction between apoE and the LDLR in the background of diabetes.  
In Chapter 4, I explore the increased risk of CVD in patients with diabetes in detail, focusing 
on the various models of diabetic atherosclerosis available to researchers and how they may 
help understand the cause of this risk.  Finally, in Chapter 6 I provide a supplemental 
examination of the the role of apoB, and in particular the LDLR binding region of apoB100, in 
the development of hyperlipidemia and atherosclerosis.  Together, this work highlights the 
importance and interconnectedness of glucose and lipid metabolism, and sheds new light on the 
critical role of apolipoprotein E in the development of dyslipidemia and atherosclerosis during 
diabetes.
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C h a p t e r  1  
INTRODUCTION 
  2 
1.1 Cardiovascular Disease 
Each year, cardiovascular disease (CVD) kills more Americans than any other cause of death. 
Diseases of the heart alone caused 30% of all deaths in 2000, with other diseases of the 
cardiovascular system causing substantially more death and disability (1).  Worldwide, deaths from 
vascular disease are estimated to rise from 16.7 million in 2002 to 18.1 million in 2011 (1).  In the 
United States alone, over 81 million people suffer from one or more of the various forms of CVD, 
including hypertension, coronary heart disease (myocardial infarction and angina pectoris), stroke, 
and heart failure (2). 
The majority of these diseases can be traced back to a single process:  atherosclerosis.  
Atherosclerosis is a condition in which fatty material collects along the walls of arteries, limiting 
the flexibility of the arteries and obstructing blood flow.  This material thickens, hardens (forming 
cholesterol crystals and calcium deposits), and occludes the vessels.  The process is thought to be 
initiated by an inflammatory injury response – in which monocytes invade the intima of the vessel 
and differentiate into macrophages (3).  Once there, the macrophages begin to phagocytose fat and 
cholesterol, in particular cholesterol-rich Low Density Lipoprotein (LDL) particles, expanding in 
size and eventually becoming ‘foam cells’, named due to their ‘foamy’ lipid-filled appearance.  At 
late stages of disease, pieces of the atherosclerotic plaque can break off and move through the 
affected artery to smaller blood vessels, blocking them and causing tissue damage or death (3). 
 
 
1.2 Lipoprotein Metabolism 
All lipoproteins consist of a triglyceride (TG) and cholesterol ester core surrounded by an outer 
shell composed of free cholesterol (un-esterified), phospholipids and various protein components.  
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They are organized into various classes as defined by their density.  LDL, like other lipoproteins, is 
a complex of lipid and protein that facilitates the transport of these crucial, but water insoluble, 
lipids through the circulation. As alluded to above, plasma LDL cholesterol level is an important 
determinant of CVD risk (4).     
Lipoprotein metabolism involves two pathways, exogenous and endogenous, which depend 
primarily on the source of the circulating lipids; dietary (exogenous) or hepatic (endogenous) 
origin (5).  Following a meal, dietary fat and cholesterol are absorbed and re-packaged by the 
enterocytes of the small intestine, and secreted into the lymphatics as chylomicrons – large TG-rich 
lipoprotein particles which eventually enter the bloodstream at the left subclavian vein (Figure 1.1).  
As they travel through the circulation, fatty acids (FA) are extracted from the chylomicron particles 
by peripheral cells through the action of Lipoprotein Lipase (LpL), leaving smaller, more dense 
Chylomicron Remnants that are eventually internalized by the liver (5). 
The liver also synthesizes cholesterol and TG and packages them into Very Low Density 
Lipoprotein (VLDL) particles, which are secreted into the circulation (6).  Peripheral tissues can 
take what they require, and VLDLs are remodeled into Intermediate Density Lipoproteins (IDL), 
and finally the more dense, cholesterol-rich LDL particles (Figure 1.1).  The liver, as well as 
peripheral tissues, can also internalize whole lipoprotein particles.  Rhe apolipoprotein components 
discussed later in this chapter are important mediators of this internalization process.  High Density 
Lipoprotein (HDL) particles mediate a process known as reverse cholesterol transport, in which the 
smaller, denser HDL particles acquire cholesterol from peripheral tissues as well as from VLDL 
and LDL and transport it back to the liver (7).  Importantly, HDL can mediate this same process in 
atherosclerotic plaques, removing cholesterol and fat from the vessel wall and returning it to the 
liver (8).   
  4 
 
 
 
 
 
Figure 1.1.  Normal Lipoprotein Metabolism. Normal lipoprotein metabolism involves uptake of 
dietary lipid, the secretion of chylomicrons, and their eventual uptake by the liver in the 
postprandial state. Conversely, during times of fasting, the liver secretes VLDL, which can be 
converted to IDL and then LDL through lipolysis.  Reverse cholesterol transport involves the 
exchange of cholesterol and apolipoproteins from VLDL and IDL particles to HDL and their return 
to the liver. Figure adapted from Lusis et al., Nature Genetics 40, 129 - 130 (2008).       
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1.3 Apolipoprotein B  
Apolipoprotein B (apoB) is a large (4536 amino acids) structural component of all lipoproteins 
with the exception of HDL.  Each lipoprotein particle contains one molecule of apoB.  ApoB is an 
essential component of chylomicrons, VLDL, IDL and LDL and normally exists in two forms, 
apoB100 and apoB48 (6).  ApoB100 is the full length protein, while apoB48 is a product of 
posttranslational mRNA editing by the apoB editing complex (apoBEC).  ApoBEC introduces a 
stop codon at 2153, resulting in a truncated version of the apoB protein (6).  ApoBEC is highly 
expressed in the intestine of humans, but it is expressed in both the intestine and liver in mice.  
Consequently, as dietary lipid is absorbed in the small intestine, it is packaged into apoB48-
containing chylomicrons and enters the lymphatic system for eventual secretion into the peripheral 
circulation (5).  In humans, apoB48 is present only on chylomicrons and chylomicron remnants, 
while all lipoproteins secreted from the liver contain apoB100.  However, due to hepatic apoBEC 
expression in mice, both apoB100 and apoB48 are secreted from the liver (6, 9). 
ApoB100 is a critical determinant of LDL cholesterol, as it functions as a ligand for the Low 
density lipoprotein receptor (LDLR).  Because the LDLR binding domain of apoB is in the C-
terminal half of the protein, apoB48 does not bind to the LDLR.  Instead, apoB48-containing 
lipoproteins require other apolipoproteins to act as a ligand for receptor binding and hence 
clearance from the circulation.  In the mouse, apoB48 is the predominant apolipoprotein 
responsible for the clearance of lipoproteins.  In fact, murine hepatic apoB48 secretion may be the 
determining factor for distinguishing mice from humans with respect to lipoprotein metabolism (6, 
9).  In Supplemental Chapter 6, “Absence of hyperlipidemia in LDL receptor-deficient mice 
having apolipoprotein B100 without the putative receptor-binding sequences”, I discuss the role of 
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apoB, and in particular the LDLR binding region of apoB100, in the development of 
hyperlipidemia and atherosclerosis  
 
 
1.4 Apolipoprotein E 
Apolipoprotein E (apoE) is a small (34 kD) circulating protein associated primarily with VLDL 
and HDL, and is the primary ligand for several lipoprotein receptors, making it a crucial 
component in the clearance of lipid from the circulation.  Its importance as a major determinant of 
plasma cholesterol and cardiovascular disease risk is underscored by the spontaneous 
hyperlipidemia and atherosclerosis in mice lacking apoE (10).  Mice lacking apoE (apoE-/-) 
accumulate cholesterol-rich remnant particles with total plasma cholesterol levels exceeding 400 
mg/dl (11).  Although diets high in fat and cholesterol accelerate plaque development, apoE-/- 
mice develop complex fully-formed atherosclerotic lesions even when fed a low fat, low 
cholesterol diet (12).   
In humans the APOE gene is polymorphic, resulting in production of three common isoforms: 
apoE2, E3, and E4.  The apoE isoforms differ from one another by only one or two amino acids at 
position 112 and 158, with E2 having cysteines at both positions, E3 a cysteine at 112 and arginine 
at 158, and E4 arginines at both positions (10).  ApoE consists of two main structural domains that 
are connected by a hinge region (Figure 1.2).  The N-terminal domain consists of a four alpha helix 
bundle containing the receptor binding region (residues 136-150).   The C-terminal domain is 
predicted as a series of alpha helices and contains the major lipid/lipoprotein binding region 
(residues 244-272).  Despite independently folding, the two domains can influence the properties 
of one another.  The cysteine /arginine amino acid residues at positions 112 and 158 influence 
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interactions between the two domains.  For instance, when the cysteine at 112 is experimentally 
replaced by an arginine in an apoE3 moleculue, the positive charge effectively pushes the arginine 
at position 61 into a position where it forms a salt bridge with glutamate 255 (13).   Consequently, 
the N-terminal domain is pulled close together with the C-terminal domain (Figure 1.3, top).  The 
modified apoE3 molecule presents a lipid binding preference for VLDL similar to that of apoE4.  
In the absence of this interaction the preference is for high density lipoproteins, as with apoE3 (13).  
The compact form of apoE4 also leads to a much lower stability than apoE3.  Likewise, apoE3 has 
a lower stability than apoE2 (14).  The interaction of the N- and C-terminal domains in apoE2 
resembles that of apoE3.  The difference between these two molecules instead arises from the 
additional cysteine residue at position 158 in apoE2, which affects the LDL receptor binding 
region by  indirectly generating an additional salt bridge with arginine 150, thereby lowering the 
overall positive charge and thus the receptor binding potential of the region (14).   
Upon binding to lipid, apoE undergoes a major conformational change (13-15).  The apoE 
molecule is thought to form a molecular envelope (horseshoe shape) around the surface of the 
phospholipid outer shell of a nascent lipoprotein particle (Figure 1.3, bottom).  Interestingly, it has 
been demonstrated that artificial lipid complexes created in vitro with apoE4 bind to the LDLR 
with a similar to slightly higher affinity than lipid complexes made with apoE3.  In contrast, 
particles made with apoE2 demonstrate a dramatically lower LDLR binding affinity (<5% 
compared to apoE3 and apoE4) (13).  When complexed with VLDL however, there is a clear 
isoform gradient in regards to cell surface receptor binding in the order of:  VLDL-4/4 (100%) > 
VLDL-3/4 (93%) > VLDL-3/3 (82%) > VLDL-4/2 (53%) > VLDL-3/2 (36%) > VLDL-2/2 (30%) 
(16).   In addition, apoE4 has been shown to have a preference to bind to triglyceride-rich VLDL, 
while apoE3 prefers to bind smaller, denser HDL particles (17).   
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Figure 1.2.  Structure and functional domains of ApoE. The N-terminal domain of apoE 
consists of a four α helix bundle (α helix 1 = red, α helix 2 = blue, α helix 3 = green, α helix 4 = 
yellow).  The LDL receptor binding domain is located in a region of α helix 4.  The C-terminal 
domain of apoE is predicted as a series of α-helices and contains the major lipid/lipoprotein-
binding region (14). 
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Figure 1.3.  Interaction of apoE N- and C-terminal domains and binding to lipid.  Top: The 
substitution of arginine for cysteine at position 112 induces structural changes in apoE3 and apoE4.  
Arg 112 in apoE4 pushes Arg 61 into a position to form a salt bridge with Glu 255.  This Arg 61 – 
Glu 255 salt bridge pulls the N- and C-terminal domains together in the apoE4 molecule.  Bottom:  
Upon binding to lipid, apoE undergoes a major conformational change, forming a circular 
molecular envelope around a phospholipid core and exposing the receptor binding region (10). 
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Even with varying distributions among different ethnic groups, E3 is overwhelmingly the most 
common isoform, with approximately 93% of the world’s population inheriting at least one copy 
(Table 1.1).  Isoform distribution varies with ethnicity.  E4 carrier frequency has been reported as 
low as 5% in Sardinia and as high as 41% in the Biaka peoples of central Africa (10).  In the 
United States, the E4 isoform occurs in 24% of the population, while the E2 allele is carried by less 
than 14% (10).   APOE genotype has been shown to affect the relative risk for several important 
diseases (Figure 1.4).  For example, patients with one or two copies of APOE4 have 10-15 mg/dl 
higher LDL cholesterol and increased rates of CVD.  Conversely, patients with a copy of APOE2 
have lower LDL, higher HDL and a decreased rate of cardiovascular events when compared to 
individuals homozygous for APOE3 (10, 15).   
APOE genotype is also strongly associated with risk and age of diagnosis for late-onset 
Alzheimer’s disease in the order of E4>E3>E2 (14).  More recent findings have pointed towards an 
involvement of apoE in glucose metabolism.  For example, several data suggest that in certain 
populations, APOE genotype is associated with plasma glucose and insulin levels (18-19) and 
postprandial glucose response (20).  APOE genotype also appears to play a role in determining the 
risk, progression and/or severity of Metabolic Syndrome (MetS) (21-22).  Studies have also 
suggested a role for ApoE in various diabetic pathologies.  For instance, an isoform-specific 
association of apoE in risk of diabetic nephropathy and retinopathy has been demonstrated in 
several cases (23).   
Most importantly in regards to CVD, diabetic apoE4 carriers have been shown to have 
increased carotid atherosclerosis (24), and elderly diabetic apoE4 carriers have an increased risk of 
CVD-associated death (25).  Human epidemiological studies, however, are difficult to conduct.  
Because the frequency of APOE2 and APOE4 homozygotes are low, most studies have been 
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carried out on heterozygous carriers in comparison to APOE3 homozygotes.  Consequently, the 
phenotypic differences observed are small and easily influenced by other concomitant factors, both 
genetic and environmental.   
  
  12
 
 
 
 
 
 
 
 
Table 1.1.  ApoE isoforms.  The three apoE isoforms have varying population distributions. The 
isoforms differ by only one or two amino acids (position 112 and 158).  However, these small 
changes result in differing affinity for the LDLr and subsequently in plasma LDL cholesterol 
concentration (10).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 apoE2 apoE3 apoE4 
Genotype:    2/2         2/3 3/3 3/4          4/4 
Population (%) 1%        12% 60% 21%         2% 
Position 112 cys cys arg 
Position 158 cys arg arg 
LDLr affinity < 5% 100% ≥100% 
LDL Cholesterol decreased normal increased 
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Figure 1.4.  ApoE isoforms, risk factors for disease.  Many different diseases have been shown 
to be affected by APOE genotype. For most disease states, the E4 allele confers risk (Right panel). 
However, for some diseases, the E2 allele confers additional risk (Left panel) (18-25). 
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1.5 Mouse Models of Human ApoE 
       Given the strong apoE isoform effect on the regulation of lipoprotein metabolism and the 
etiology of cardiovascular disease, it is essential for researchers to have access to translatable 
mouse models in which to study these effects.  To this point, our laboratory has generated mice 
that express human apoE2, apoE3 and apoE4 using targeted gene replacement techniques (26).  
These mice have had the coding sequences for mouse apoE carefully replaced with coding 
sequences for the various human apoE isoforms.  The replaced genomic fragment contains the 3′ 
part of intron 1, exons 2–4 of the human APOE gene, and 1.5 kb of 3′-flanking DNA, while the 5’ 
and 3’ portions of the mouse gene remain intact.  Thus, the targeted replacement mice retain their 
endogenous mouse APOE promoter and all cis elements that are known to be important for the 
regulation of the APOE gene.  Mice targeted in this manner express human apoE mRNA in a 
similar tissue distribution and at a level indistinguishable from mouse apoE mRNA is expressed in 
wild type mice (27). 
      Mice that express human apoE2 (E2) have severely elevated plasma lipids closely resembling 
the human lipoprotein disorder known as type III hyperlipidemia.  Type III hyperlipidemia is 
characterized by elevated levels of chylomicrons and VLDL and the most common causal factor is 
the homozygosity for APOE2 (28).  Yet less than 5% of homozygous APOE2 individuals develop 
type III hyperlipidemia.  In addition, its onset is about 30 years of age in men, but post-menopausal 
in women (28).  In contrast to humans, both young male and female E2 mice have plasma 
cholesterol and triglyceride levels 2-3 times higher than wild type mice and mice with human 
apoE3 (Figure 1.5).  Consequently, the E2 mice develop atherosclerosis even on a low fat diet (26).   
As expected, mice expressing E2 show a significant reduction in their clearance of circulating 
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VLDL.  Therefore, the severe hyperlipidemia observed in the E2 mice correctly reflects the low 
affinity of E2 for the LDLr. 
      The replacement of mouse apoE with human apoE3 or human apoE4 leads to total plasma 
lipids and lipoprotein profiles similar to mice with wild type mouse apoE (Figure 1.5) (26-27).  E3 
and E4 mice do not differ significantly in total plasma lipid or apolipoprotein levels.   No 
atherosclerosis develops in these mice, even when a Western type diet is administered.  However, 
when challenged with a high fat diet containing 15% fat, 1.25% cholesterol and 0.5% sodium 
cholate, both E3 and E4 mice had 3-4 times higher total plasma cholesterol and significantly larger 
atherosclerotic plaques compared to wild type mice (26-27).  However, E4 mice accumulated more 
cholesterol-rich VLDL compared to mice with E3.  In addition, E4 expressing mice tended to have 
larger atherosclerotic plaques on the atherogenic diet (26-27).  In both Chapter 2 and Chapter 3, I 
have employed these useful humanized mouse models in order to examine the previously 
uninvestigated role of apoE in the setting of diabetes. 
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Figure 1.5.  Lipoprotein profiles in human apoE mice.  Mice homozygous for APOE2, E3, or E4 
were fed a Western type diet containing 21% fat and 0.15% cholesterol.  Cholesterol (white 
circles) and triglyceride (black circles) distribution among various lipoprotein fractions in human 
apoE mice.  Lipoprotein fractions were separated by fast performance liquid chromatography 
(FPLC).  Fractions 12-17 correspond to VLDL, 19-25 to LDL, and 28-32 to HDL.  E2 mice have 
2-3 times higher total plasma cholesterol and triglycerides due to a defect in the clearance of 
VLDL and develop atherosclerosis even on a low fat diet.  Mice with E3 and E4 have very similar 
lipid distribution patterns, with the majority of plasma cholesterol residing in the HDL fractions.  
(26-27, 29) 
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1.6 Low Density Lipoprotein Receptor 
      The major receptor through which apoE mediates lipoprotein clearance is the LDLR, and the 
apoE isoforms exhibit differential LDLR binding affinities (15).  The LDLR is an 840 amino acid 
transmembrane receptor belonging to the low density lipoprotein receptor gene family.  LDLR 
protein synthesis is regulated by the level of free cholesterol within the cell.  High intracellular 
cholesterol results in an inhibition of LDLR expression while depleted intracellular cholesterol 
levels stimulate transcription (25).  LDLR complexes are found at the cell surface in clathrin-
coated pits.  The LDLR recognizes both apoE and full length apoB100, binding and then 
internalizing the apoE and apoB100 containing lipoprotein particles within a clathrin-coated 
vesicle (30).  The LDLR contains a series of seven sequence repeats of negative charge at the N-
terminus known as the class A domain.  Binding of apoB requires class A repeats 2-7 while 
binding of apoE requires only repeat 5 (31).   As mentioned earlier, the apoE isoforms demonstrate 
a binding affinity to the LDLR in the order of E2 << E3 ≤ E4 (13).  Lipoprotein size also 
determines apoE binding epitope availability and even though the binding repeats of apoE are 
exposed during its lipid-free state, high affinity binding to the LDLR does not occur until apoE is 
complexed with lipid (31-33).  Following endocytosis, the vesicle fuses with a late endosome and 
the acidic change in pH results in a conformational change to the receptor that releases the bound 
lipoprotein particle.  The LDLR, as well as apoE, is then either degraded or recycled back to the 
cell surface where the neutral pH results in a change back to native conformation (Figure 1.6) (23, 
34-35). 
      Defects in the LDLR in humans result in familial hypercholesterolemia (FH), a genetic disorder 
characterized by abnormally high plasma lipids (36).  Due to the LDLR’s important role in 
clearing LDL from the circulation, these patients suffer from chronic elevations in plasma 
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cholesterol and premature atherosclerosis.  Mice deficient in the LDLR have lower total plasma 
cholesterol levels (~200 mg/dl lower) than their apoE-/- counterparts (>400 mg/dl).  However, the 
majority of this cholesterol is in the form of the highly atherogenic LDL (37).  Despite the 
differences in lipoprotein distribution between the two models, the pathology of atherosclerosis in 
both the apoE-/- and Ldlr-/- mice is very similar to that seen in humans.   Beginning as small foam 
cell formations deposited along the vessel wall, the lesions progress to large mature plaques 
containing a fibrous cap, necrotic core with cholesterol deposits and calcifications and thickening 
of the medial and adventitial tissue (11-12).   The capability to model human-like atherosclerotic 
plaques in these mice has provided scientists with an experimental system in which to study 
multiple facets of disease progression as well as investigate potential therapies.  In Chapter 2, I 
used mice deficient in LDLR in order to examine the effect of the human apoE isoforms on the 
progression of diabetic atherosclerosis. 
  
  19
 
 
 
Figure 1.6.  Receptor-mediated uptake and processing of lipoproteins in the liver.  Left:  
Lipoproteins (small black circles) enter the space of Disse (SD) where they bind to cell surface 
lipoprotein receptors such as the LDLR (Y shape).  The receptors are then internalized with their 
lipoprotein cargo in clathrin-coated pits, forming primary endosomes.  The acidic pH of the sorting 
endosome stimulates the receptors to release their lipoproteins and dissociate from the clathrin 
coat.  The lipoproteins are then transported to multivesicular bodies (MVB), or late endosomes, 
and eventually make their way to the lysosome. Recycling endosomes carry the receptors back to 
the cell surface.  Right:  Enlargement of a hepatic microvillus (H) and its adjacent endothelial cells 
(E).  VLDL remnants pass through the endothelial cell fenestrae to the SD where they bind via 
apoE to LDLR or other members of the receptor family such as the LDLR related protein (LRP) 
and proteoglycans.  Hepatic lipase bound to proteoglycans hydrolyzes lipids from the remnant 
particles (21). 
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1.7 Overexpression of the LDLR 
      According to conventional wisdom, increasing expression of the LDLR is considered 
beneficial for reducing plasma cholesterol and atherosclerosis, as the LDLR works to clear 
atherogenic lipoprotein particles from the circulation.  The high affinity of apoE4 for the LDLR 
has been proposed to lead to increased apoE-mediated cholesterol uptake, higher intracellular 
cholesterol and thus a subsequent down-regulation of LDLR expression (38).  Down-regulated 
LDLR levels would then lead to a reduction in apoB100-mediated LDL clearance and thus high 
levels of circulating LDL cholesterol and an increase in atherosclerosis.  This hypothesized 
downregulation of the LDLR by apoE4 has been thought to explain the association between apoE4 
and increased risk of CVD.    
      Contrary to this hypothesis, our laboratory has previously shown that increased Ldlr expression 
caused severe atherosclerosis in mice with human apoE4, but not apoE3, when the animals were 
fed a high fat diet (38).  The mice used in these studies are heterozygous for targeted replacement 
of the mouse Ldlr gene with a human LDLR minigene (Ldlrh/+) that produces stabilized mRNA 
with a longer than normal half-life.  As a result, carriers of the stabilized human LDLR minigene 
have steady state LDLR expression levels 2-3 times higher than wild type mice (38).  To examine 
the interaction between the human apoE isoforms and LDLR, human apoE mice were crossed with 
Ldlrh/+ mice (E2h, E3h and E4h).  Overexpression of the LDLR ameliorates the hyperlipidemia 
observed in the E2 mice and rendered them resistant to diet-induced atherosclerosis (Figure 1.7) 
(39).  Increasing LDLR expression in apoE3-expressing mice resulted in a reduction in HDL 
cholesterol, but had no significant effect on non-HDL cholesterol or the development of 
atherosclerosis.  However, increasing LDLR expression in apoE4-expressing mice resulted in the 
marked accumulation of cholesterol-rich, apoE-poor VLDL remnant particles and the development 
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of distinct atherosclerotic plaques when the mice were fed a high fat diet (Figure 1.7).  Thus, the 
human apoE mice expressing increased LDLR exhibit lipoprotein distributions more similar to 
those associated with APOE genotype in humans.  We believe this is a result of apoE “trapping”, 
whereby the LDLR binds and traps apoE to the point where the supply available for lipoprotein 
binding becomes inadequate (38).  ApoE exchange onto lipoproteins is required for efficient 
internalization by the LDLR, and without adequate apoE to mediate this process, these lipoproteins 
can become stuck in the circulation.  We propose that apoE4 may be particularly sensitive to this 
process of trapping due to its strong affinity for the LDLR.  In Chapter 3, I use this same human 
apoE, increased LDLR model to examine the effects of the apoE-LDLR interaction in the 
background of diabetes. 
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Figure 1.7.  Lipoprotein profiles of human apoE mice overexpressing the LDLR.  Cholesterol 
(white circles) and triglyceride (black circles) distribution among various lipoprotein fractions in 
human apoE mice overexpressing the LDLR and challenged with a Western type diet.  Human 
apoE2 expressing mice with increased LDLr expression (E2h) and human apoE3 expressing mice 
with increased LDLr expression (E3h) mice carry the majority of their cholesterol within the HDL 
fractions.  However, overexpression of the LDLR in the presence of E4 (E4h) results in a harmful 
increase in VLDL and VLDL remnant cholesterol in addition to reduced HDL cholesterol, leading 
to the development of atherosclerosis (38).  
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1.8 Diabetes  
In addition to the heavy financial and health burden of CVD, over 7% of the United States 
population has been diagnosed with diabetes (40-43).   Diabetes mellitus is a disorder of glucose 
metabolism, defined as fasting plasma glucose level ≥ 7.0 mmol/L (126 mg/dL) or plasma glucose 
≥ 11.1 mmol/L (200 mg/dL) two hours following an oral glucose challenge (75 gram load) during 
a glucose tolerance test (44).  Diabetes is traditionally divided into two subsets, type 1 or type 2 
diabetes.  Type 1 diabetes, formerly referred to as as insulin-dependent diabetes mellitus (IDDM) 
or juvenile diabetes, results from pancreatic failure to produce insulin.  Type 2 diabetes, formerly 
referred to as non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes, is a result 
of insulin resistance, a condition in which cells fail to efficiently respond to insulin, and can be 
accompanied by insulin deficiency at late stages of the disease (44).  Several debilitating 
complications are associated with the progression of diabetes.  These include hypertension, 
retinopathy, neuropathy, nephropathy, and infection (45).   
The damage done by diabetes extends far beyond the typical complications described above, as 
diabetics are four to five times more likely to develop CVD than non-diabetic patients (40-43).   
Cardiovascular disease caused by atherosclerosis is an important complication of diabetes, and is 
the leading cause of mortality among patients with diabetes, accounting for 65% of all deaths (40-
43).  The epidemic of obesity and Metabolic Syndrome (MetS) means millions of additional 
Americans will soon find themselves with a severely increased risk of developing CVD (42).  
Chapter 4, “Macrovascualar complications of diabetes in atherosclerosis-prone mice”, discusses 
the increased risk of CVD in patients with diabetes in detail, and explores the plethora of mouse 
models of diabetic atherosclerosis available to researchers aiming to unravel the source of this risk. 
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The increased risk of CVD in patients with diabetes can be attributed to several factors, 
including the following.  Hyperglycemia can lead to endothelial dysfunction, as the chronic 
elevation of blood glucose level can lead to angiopathy (46).  The endothelial cells lining the blood 
vessels take in more glucose than normal, as they rely on an insulin-independent method of 
glucose uptake. These cells then form more surface glycoproteins than normal, and cause the 
basement membrane to grow thicker and weaker (46).   Diabetes is also commonly accompanied 
by an increase in inflammation and a pro-thrombotic state (47).  Elevated concentrations of C-
reactive protein (CRP), an acute phase reactant, has been associated with diabetes, and an increase 
in fat mass, as often seen in MetS and type 2 diabetes, can lead to release of adipose tissue specific 
inflammatory molecules, or adipokines.  Patients with insulin resistance also frequently manifest 
several alterations in coagulation mechanisms.  These alterations include increased fibrinogen 
levels, increased plasminogen activator inhibitor-1 (PAI-1), and various platelet abnormalities (47).  
Hypertension often occurs in obese, MetS and type 2 diabetes patients, and has been shown to be 
postively correlated with insulin resistance (48).  Hypertension nearly doubles the risk for CVD, 
and compared to the other modifiable risk factors described above, high blood pressure has the 
largest impact on CVD mortality (48-50). 
 
 
1.9 Models of Diabetes 
      Numerous models of diabetes have been employed by researchers to date, including chemical, 
diet-induced, and genetic models of both type 1 and type 2 diabetes.  These models, as well as the 
common models of atherosclerosis introduced earlier, are described in detail in Chapter 4.  Due to 
their simplicity, mouse models of type 1 diabetes are the most commonly used animal models of 
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diabetes, despite representing only 10% of patients with diabetes (51-52).  The most commonly 
used model of type 1 diabetes is chemically induced by the drug streptozotocin (STZ).  STZ is a 
DNA alkylating agent that is particularly toxic to the pancreas as its uptake is mediated through 
glucose transporter 2 (Glut2) receptors, which are abundant in pancreatic β-cells (53).  Repeated, 
low dose injection of STZ results in insulin deficiency and hyperglycemica with minimal toxic side 
effects to other cell types (54).  In Chapter 2, I used STZ to induce diabetes in the well-established 
LDLR deficient model of atherosclerosis. 
      Genetic models of type 1 diabetes are also available to researchers, including non-obese 
diabetic (NOD) mice.  Mirroring the islet cell autoimmunity thought to contribute to type 1 
diabetes in humans, NOD mice begin to develop diabetes at an early age due to immune cell 
infiltration of the pancreatic islets (55).  The studies described in Chapter 3 employ another genetic 
model of type 1 diabetes, the “Akita” mutation.  Akita mice spontaneously develop diabetes due to 
a missense mutation (C96Y) in the insulin 2 (Ins2) gene that disrupts a disulfide bond between A 
and B chains of insulin and leads to improper folding of insulin and eventual pancreatic β-cell loss 
(56).  The non-obese, insulin deficient Akita mice develop progressive hyperglycemia, and are an 
established model in which to study diabetic complications such as retinopathy and nephropathy 
(57-58), as well as diabetic atherosclerosis (59).  Male mice heterozygous for the Ins2 Akita 
mutation (Ins2+/-) develop diabetes as early as 2 months of age, making them an attractive genetic 
model of type 1 diabetes. 
       The metabolic syndrome (MetS) is a cluster of metabolic disturbances that include insulin 
resistance, hypertension, obesity and dyslipidemia (48).  These metabolic disturbances predispose 
patients to the development of type 2 diabetes.  Consequently, the vast majority of mouse models 
of type 2 diabetes lean heavily on one or more of these disturbances as a model system.  Frequently 
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employed methods to induce type 2 diabetes in the mouse rely on insulin resistance and/or obesity 
brought about by genetic or dietary means (51).  The most common obesity-induced models of 
type 2 diabetes are the leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice.  
Deficiencies in the leptin signaling pathway in these mice lead to hyperphagia, obesity and 
consequent insulin resistance (60).  Other genetic models, such as the insulin receptor substrate 
protein 2 (IRS2) deficient mice, introduce partial or complete deficiencies in insulin receptors to 
mimic the pathophysiology of insulin resistance.   
 
 
1.10 Diabetic Dyslipidemia 
An important potential explanation for the increased CVD risk associated with diabetes is 
diabetic dyslipidemia, a common cluster of harmful changes in lipid metabolism frequently noted 
in patients with diabetes (61).  Both poorly managed type 1 diabetes and type 2 diabetes lead to 
harmful modifications of lipoprotein metabolism.  Specifically, there are four distinct changes 
noted in patients with diabetes:  1) postprandial lipemia, 2) elevated very low density lipoprotein 
(VLDL) triglycerides, 3) a reduction of high density lipoprotein (HDL) cholesterol, and 4) smaller 
average LDL particle size (Figure 1.8, orange arrows).   
The rate of clearance of chylomicrons from the bloodstream is often slower in patients with 
untreated type 1 or type 2 diabetes compared with normal subjects.   The liver is the primary site of 
remnant clearance, and alterations in various LDL receptor family members such as LDLR and 
LRP  during diabetes may contribute to this slower postprandial lipid clearance (61).   
There is an increase in the production and secretion of VLDL by the liver in patients with 
diabetes, particularly in those with type 2 diabetes (61-64).  Thus, patients with diabetes are often 
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hypertriglyceridemic.  Insulin down-regulates the process of VLDL secretion, and reduces plasma 
fatty acid levels – a determinant of hepatic VLDL flux.  The increase in VLDL production in 
patients with diabetes is alleviated by the administration of insulin (64).   
HDL cholesterol is reduced during diabetes, possibly as a result of the increase in VLDL TG 
described above.  Lipids are frequently exchanged between lipoproteins in circulation, and an 
increase in plasma concentrations of TG-rich VLDL could lead to decreased HDL cholesterol as 
VLDL TG is exchanged for HDL cholesterol esters (65). 
Lastly, while total LDL is not usually increased during diabetes, a decrease in the size and an 
increase in density of LDL are often noted (61, 66).  Smaller, more dense LDL is more likely to 
undergo detrimental modifications such as oxidation and glycation, making it preferentially taken 
up by foam cells, leading to atherosclerosis (61). 
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Figure 1.8.  Diabetic Dyslipidemia.  The orange arrows signify the three common changes that 
occur in diabetic dyslipidemia:  1) an increase in VLDL triglycerides, 2) an increase in small, 
dense LDL, and 3) a decrease in HDL cholesterol.  In many cases, diabetic dyslipidemia is 
associated with hepatic dysfunction, including increased VLDL secretion and an increase in 
hepatic lipid content (orange circles) (71).  
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1.11 ApoE in Diabetes 
I hypothesize that ApoE, an essential mediator of lipid metabolism in normolipidemic patients,  
plays a major role in diabetic dyslipidemia as well (Figure 1.9).  Increases in VLDL triglycerides, 
decreases in HDL, the accumulation of smaller/denser LDL, slower clearance of postprandial 
chylomicrons, a decrease in lipoprotein lipase (LPL) activity, and a decrease in LDLR expression, 
are all commonly noted phenotypes associated with both type 1 (insulin dependent) and type 2 
(non-insulin dependent) diabetes (61).  Interestingly, all of these components of dyslipidemia are 
areas of lipid metabolism in which ApoE has previously been shown to play a direct role.  In 
Chapter 2, “Human apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in 
mice lacking the LDL receptor”, I examine the role of the human apoE isoforms in the regulation 
of dyslipidemia and atherosclerosis during diabetes. 
While the process of dyslipidemia is a critical determinant of cardiovascular disease during 
diabetes, there are many other potential contributing factors, as described in Section 1.5 and in 
detail in Chapter 3.  Separating these lipid-independent effects of diabetes on cardiovascular 
disease from the effects of diabetes-induced hyperlipidemia has long been a problem for 
researchers. To date, all current mouse models in which diabetes exacerbates atherosclerosis suffer 
from severe diabetes-induced hyperlipidemia, making it incredibly difficult to separate the lipid 
dependent and independent effects of diabetes (51-52, 61).   
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Figure 1.9.  Central hypothesis.  ApoE plays an essential role in the modulation of diabetic 
dyslipidemia, serving as a critical link between the processes of glucose and lipoprotein 
metabolism. 
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Along these lines, there may be additional roles for apoE during diabetes outside its effects on 
the regulation of dyslipidemia.  For example, the apoE4 isoform has been shown to be a less 
efficient inhibitor of glycation and oxidation compared to the E3 and particularly the E2 isoform.  
Modifications such as glycation and oxidation to the cells of the vessel wall, and especially to LDL 
particles themselves, are highly atherogenic and occur more frequently in the diabetic setting (67-
69).   In addition, our laboratory previously demonstrated that in macrophages, the apoE-LDLR 
dynamic changes dramatically depending on apoE isoform, resulting in significant alterations in 
atherosclerotic plaque development without affecting plasma lipids.  For example, in mice 
expressing E3, the introduction of LDLR-overexpressing macrophages by bone marrow transplant 
had no effect on atherogenesis.  However, in mice expressing E4, the transplant of LDLR-
overexpressing macrophages led to a significant increase in atherosclerotic plaque size (70).  
Plasma lipid-independent mechanisms such as the ones noted above, in which apoE has been 
shown to have a strong effect in normal settings, may also play an important role in the background 
of diabetes.  In Chapter 3, I explore these potential effects of apoE by describing a novel model of 
diabetic atherosclerosis, one in which apoE4 lends atherosclerotic potential in the absence of 
diabetes-induced hyperlipidemia. 
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C h a p t e r  2  
 
APOLIPOPROTEIN E4 EXAGGERATES DIABETIC DYSLIPIDEMIA AND 
ATHEROSCLEROSIS IN MICE LACKING THE LDL RECEPTOR45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(This chapter consists of material from a manuscript reprinted with permission from Diabetes; 
2011; titled “Human Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in 
mice independently of the LDL receptor” by Lance A Johnson, Jose Arbones-Mainar, Raymond G 
Fox, Hyung-Suk Kim, Avani Pendse, Michael K Altenburg, Hyung-Suk Kim and Nobuyo Maeda) 
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2.1 Summary 
 
Objective - We investigated the differential roles of apolipoprotein E (apoE) isoforms in 
modulating diabetic dyslipidemia – a potential cause of the increased cardiovascular disease risk of 
patients with diabetes.  Research Design and Methods – Diabetes was induced using streptozotocin 
(STZ) in human apoE3 (E3) or human apoE4 (E4) mice deficient in the low density lipoprotein 
receptor (LDLR-/-).  Results - Diabetic E3LDLR-/- and E4LDLR-/- mice have indistinguishable 
levels of plasma glucose and insulin.  Despite this, diabetes increased VLDL triglycerides and 
LDL cholesterol in E4LDLR-/- mice twice as much as in E3LDLR-/- mice.  Diabetic E4LDLR-/- 
mice had similar lipoprotein fractional catabolic rates compared to diabetic E3LDLR-/- mice, but 
had  larger hepatic fat stores and increased VLDL secretion.  Diabetic E4LDLR-/- mice 
demonstrated a decreased reliance on lipid as an energy source based on indirect calorimetry.  
Lower phosphorylated Acetyl-CoA Carboxylase content and higher gene expression of fatty acid 
synthase in the liver indicated reduced fatty acid oxidation and increased fatty acid synthesis.  
E4LDLR-/- primary hepatocytes cultured in high glucose accumulated more intracellular lipid than 
E3LDLR-/- hepatocytes concomitant with a 60% reduction in fatty acid oxidation.  Finally, the 
exaggerated dyslipidemia in diabetic E4LDLR-/- mice was accompanied by a dramatic increase in 
atherosclerosis.  Conclusions – ApoE4 causes severe dyslipidemia and atherosclerosis independent 
of its interaction with LDLR in a model of STZ-induced diabetes. ApoE4 expressing livers have 
reduced fatty acid oxidation, which contributes to the accumulation of tissue and plasma lipids. 
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2.2 Introduction 
 
Cardiovascular disease (CVD) caused by a worsening of atherosclerosis is an important 
complication of diabetes and is the leading cause of mortality among patients with diabetes (1).  
Patients with poorly managed type 1 diabetes or type 2 diabetes commonly have elevated very low 
density lipoprotein (VLDL) triglycerides, a reduction of high density lipoprotein (HDL) 
cholesterol, and smaller, dense LDL.  This common cluster of harmful changes in lipid metabolism 
is referred to as diabetic dyslipidemia (2). 
         Apolipoprotein E (apoE) is a small circulating protein associated predominantly with VLDL 
and HDL.  It is the primary ligand for several lipoprotein receptors, making it a crucial component 
in the clearance of lipid from the circulation and a major determinant of plasma cholesterol and 
CVD risk (3).  In humans, the APOE gene is polymorphic, resulting in production of three 
common isoforms: apoE2, apoE3, and apoE4.  The apoE4 isoform is carried by over a quarter 
(28%) of the US population, and is associated with higher LDL cholesterol and an increased risk of 
CVD (3).  In addition to its well-established role in CVD, recent findings have implicated a role for 
apoE in glucose metabolism as well.  Epidemiological studies have suggested that in certain 
populations APOE genotype may influence plasma glucose and insulin levels (4, 5), postprandial 
glucose response (6), the development of Metabolic Syndrome (7, 8), and a myriad of diabetic 
complications (9).  In addition, apoE4 carriers with diabetes have been shown to have increased 
carotid atherosclerosis (10), and elderly apoE4 carriers with diabetes have an increased risk of 
CVD-associated death (11). 
        Increases in VLDL triglyceride, decreases in HDL, the accumulation of smaller more dense 
LDL, slower clearance of post-prandial chylomicrons and a decrease in LDL receptor (LDLR) 
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expression are all noted phenotypes associated with both type 1 and type 2 diabetes (2).  All of 
these components of diabetic dyslipidemia are areas of normal lipid metabolism in which apoE has 
previously been shown to play a direct role.  The major receptor through which apoE mediates 
lipoprotein clearance is the LDLR, and the apoE isoforms exhibit differential LDLR binding 
affinities (12).  Therefore, we sought whether apoE isoforms retain differential roles in diabetic 
dyslipidemia and atherosclerosis in the absence of the LDLR by employing a mouse model of 
diabetes induced by streptozotocin (STZ). 
           In this study, we show that dyslipidemia and atherosclerosis are greatly exaggerated in 
diabetic LDLR-/- mice expressing human apoE4 (E4LDLR-/-) compared to those with human 
apoE3 (E3LDLR-/-), despite a similar degree of hyperglycemia.  This E4-specific aggravation of 
diabetic dyslipidemia is central to the liver, and is associated with a reduction in hepatic lipid 
oxidation, an accumulation of liver triglycerides, and increased rates of VLDL secretion. 
 
 
2.3 Methods 
 
Mice and induction of diabetes   
            Mice homozygous for replacement of the endogenous Apoe gene with the human APOE*3 
(E3) or APOE*4 (E4) allele (13,14) were crossed with mice deficient in the LDLR (15).  All mice 
were on C57BL/6 backgrounds.  Male mice were fed normal chow diet ad libitum (5.3% fat and 
0.02% cholesterol) (Prolab IsoPro RMH 3000; Agway Inc). Diabetes was induced at 2 months of 
age by peritoneal injections of streptozotocin (STZ) for 5 consecutive days (0.05 mg/g body weight 
in 0.05 M citrate buffer, pH 4.5).  Mice maintaining glucose levels >300 mg/dl throughout the 
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course of the study are considered “Diabetic”.  “Non-diabetic” control mice were injected with 
vehicle citrate buffer.  Biochemical analyses were carried out at 1 month post-STZ unless 
otherwise stated. Animals were handled under protocols approved by the Institutional Animal Care 
and Use Committees of the University of North Carolina. 
 
Biochemical assays 
             After a 4 hour fast, animals were anesthetized with 2,2,2-tribromoethanol and blood was 
collected. Plasma glucose, cholesterol, phospholipids, free fatty acids and ketone bodies were 
measured using commercial kits (Wako). Triglycerides and insulin were determined using 
commercial kits from Stanbio and Crystal Chem Inc., respectively.  Liver triglycerides were 
extracted as described (16).  Lipoprotein distribution and composition was determined with pooled 
(n=6-8) plasma samples (100µl) fractionated by fast protein liquid chromatography (FPLC) using a 
Superose 6 HR10/30 column (GE Healthcare).  Pooled plasma (800 µl) was separated by 
sequential density ultracentrifugation into density fractions from <1.006 g/ml (VLDL) to >1.21 
g/ml (HDL) and subjected to electrophoresis in a 4-20% denaturing SDS-polyacrylamide gel (17).  
Carboxylmethyl lysine (CML) advanced glycation end products (AGEs) were measured using an 
ELISA with antibodies specific for CML-AGEs (CycLex, Nagano, Japan).   Apolipoprotein E and 
apolipoprotein CIII were measured using an ELISA with antibodies specific for apoE 
(Calbiochem) and apoCIII (Abcam).  Protein expression by western blot was determined using 
antibodies against AMPKα, phosphorylated (Thr172) AMPKα, ACC, phosphorylated (Ser79) 
ACC, and β-actin (Cell Signaling). Lipid tolerance test was performed by gavaging 10 ml/kg 
olive oil following an overnight fast.  For VLDL secretion, plasma TG was measured following 
injection of Tyloxapol (Triton WR-1339; Sigma ) via tail vein (0.7 mg/g BW) after a 4 hour fast 
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(18).  VLDL lipolysis was estimated by incubating VLDL (25 µg TG in 60 µl PBS) at 37° C 
with15U of bovine lipoprotein lipase (Sigma). The reaction was stopped by adding 3 µl of 5M 
NaCl, and fatty acid release (FAtimepoint  - FA0) was measured as above.  
 
Lipoprotein clearance 
           VLDL and LDL were labeled with 1,1' - Dioctadecyl - 3,3,3',3' - 
tetramethylindocarbocyanine iodide (DiI) or I125 as previously described and injected to recipient 
mice via the tail vein (100 µg DiI-VLDL or 5 x 105 counts I125 lipoproteins, diluted in 200 µl of 
PBS)  (18).  Plasma fluorescence was measured using an Olympus FV500 (Texas Red filter) with a 
SPOT 2 digital camera. Radioactivity was counted on a Wallac 1470 Wizard Gamma Counter 
(EG&G Wallac).   
 
Lipid and glucose uptake, DNL and oxidation 
             Primary hepatocytes were isolated from 3 month old mice as described (19).  Yield ranged 
from 3 to 6 x 106 cells/g liver, and viability (assessed by Trypan blue staining was >90%.  
Following overnight culture in hepatocyte media (Xenotech), cells (100,000/well, 24-well plate) 
were washed and cultured 72 hours in DMEM supplemented with 5% fetal bovine serum (v/v) 
with 5 mM (Low) or 25 mM (High) glucose.  Prior to dilution, [1-14C]-Palmitic Acid was re-
suspended in 1% BSA solution.  For oxidation measurements, cells were incubated for 2 hours 
with 1 µCi/ml D-[1-14C]-Glucose or 1 µCi/ml [1-14C]-Palmitic Acid (Perkin Elmer) while CO2 was 
trapped using a customized 48-well NaOH trap (20). For 2-Deoxyglucose uptake, hepatocytes 
were starved in serum-free medium containing 135 mmol/l NaCl, 5.4 mmol/l KCl, 1.4 
mmol/lCaCl2, 1.4 mmol/l MgSO4, and 10 mM Na4P2O7 for 30 min and then incubated for 10 
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min with 1 µCi/ml 2-Deoxy-D[1-3H]glucose (Perkin-Elmer).  For fatty acid uptake and 2-
Deoxyglucose uptake, cells were washed 3x with ice-cold HBSS, lysed in 1 ml of 1% SDS and 
radiation counted.  To estimate de novo lipogenesis, cells were incubated with 1 µCi/ml D-[1-14C]-
Glucose for 24 hours, washed 3x with PBS, scraped in 1 ml of methanol:PBS (2:3) and freeze 
thawed in liquid nitrogen. The lipid layer was then extracted using a chloroform:methanol (2:1) 
extraction. Radiation was counted in 5 ml SX18-4 Scinteverse BD scintillation fluid (Fisher) using 
a LKB Wallac 1214 RackBeta liquid scintillation counter (Spectrofuge) 
 
Indirect Calorimetry   
            Mice were placed in a calorimetry system (LabMaster; TSE Systems) for 48 hours and 
monitored for O2 consumption, CO2 production, and RQ (RQ = VCO2 / VO2, where V is volume).  
Activity was determined by counting the number of breaks in light barriers on the X, Y, and Z axis. 
 
 
Atherosclerosis   
             After 3 months of diabetes, mice were euthanized with a lethal dose of 2,2,2-
tribromoethanol and perfused at physiological pressure with 4% phosphate buffered 
paraformaldehyde (pH 7.4).  Morphometric analysis of plaque size at the aortic root was performed 
as described (19).  Apoptotic cells were detected in 8 µm frozen sections of the aortic root with a 
kit that detect DNA fragmentation (Chemicon).  Macrophages were detected with a 1:500 dilution 
of MOMA-2 (Abcam) and a 1:2000 dilution of Goat polyclonal Secondary Antibody to Rat IgG - 
H&L Cy5 (Abcam).   
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2.4 Results 
 
Induction of diabetes   
            E3LDLR-/- and E4LDLR-/- mice had indistinguishable plasma glucose levels at the 
beginning and at the end of the study (Figure 2.1A, Table 2.1).  They showed a similar response 
rate to STZ, with 86.4 and 84.6% of injected E3LDLR-/- and E4LDLR-/- mice becoming diabetic.  
One month after STZ injection, average plasma glucose levels of E3LDLR-/- and E4LDLR-/- mice 
reached 424 ± 30 and 407 ± 44 mg/dl, respectively, and remained >400 mg/dl for the 3 month 
study period (Figure 2.1A, Table 2.1).  Plasma insulin levels in both genotypes dropped severely 
(Figure 2.1B).  The severity of diabetes was also comparable between the two diabetic groups as 
estimated by plasma levels of ketone bodies, daily food intake and urine excretion (Table 4.1).    
 
Diabetic dyslipidemia   
             Non-diabetic E3LDLR-/- and E4LDLR-/- mice had similar total plasma cholesterol and 
triglycerides (Figure 2.2A-B) as well as similar lipoprotein distribution profiles (Figure 2.2C-D).  
While the induction of diabetes led to increases in total cholesterol and total triglycerides in both 
E3LDLR-/- and E4LDLR-/- mice as early as 1 month after STZ treatment, the increase in plasma 
cholesterol was significant only in E4LDLR-/- mice when compared to their non-diabetic 
counterparts.  Most importantly, plasma cholesterol and triglycerides in the diabetic E4LDLR-/- 
mice were significantly higher than those in diabetic E3LDLR-/- mice at 1 and 3 months of 
diabetes (Figure 2.2A-B). 
VLDL and LDL cholesterol, as well as VLDL triglycerides, increased in both genotypes after 
STZ treatment (Figure 2.2E-F).  However, VLDL triglycerides and LDL cholesterol were both 
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two-fold higher in E4LDLR-/- mice than in E3LDLR-/- mice (Figure 2.2E-F).  Consequently, the 
LDL to HDL ratio, an established risk factor for atherosclerosis, was 2.2-fold higher in diabetic 
E4LDLR-/- mice than in diabetic E3LDLR-/- mice.  Given that the diet provided was low in fat 
and cholesterol, and food consumption did not differ between the two diabetic groups (Table 2.1), 
the enhanced hyperlipidemia in E4LDLR-/- is independent of dietary lipid intake. 
        VLDL fractionated from plasma by sequential ultracentrifugation had a similar composition 
of cholesterol, triglycerides, and phospholipids (Figure 2.3A).  Diabetes induced a 5 and 26% 
increase in apoB100 and a 10 and 57% increase in apoB48 in E3LDLR-/- and E4LDLR-/- mice, 
respectively.  Although total amounts of apoB100 and apoB48 are approximately 30% more in the 
diabetic E4LDLR-/- mice compared to diabetic E3LDLR-/- mice, their distributions among 
different classes of lipoproteins were not significantly altered (Figure 2.3B-E).  Similarly, the 
amount of total plasma ApoA1 did not differ by apoE genotype (Figure 2.3F-G).  Diabetic 
E3LDLR-/- and diabetic E4LDLR-/- mice had similar lipoprotein distributions of apoE (Figure 
2.4A-B) and apolipoprotein CIII to apoE ratios, an important marker of lipolysis and uptake 
(Figure 2.4C).  Rates of lipolysis were also similar between VLDL isolated from diabetic 
E3LDLR-/- or diabetic E4LDLR-/- mice (Figure 2.4D),  suggesting similar rates of VLDL 
conversion between the two diabetic groups.   In addition, the degree of glycation in the VLDL-
LDL lipoprotein fractions was similar in all groups (Table 2.1).  In summary, diabetic E4LDLR-/- 
mice develop a far more deleterious plasma lipid and lipoprotein distribution profile than diabetic 
E3LDLR-/- mice, characterized by a substantial increase in the total amount of circulating 
lipoproteins, although not in the composition of the lipoprotein particles themselves. 
  
Figure 2.1.  Induction of diabetes.  
squares) and non-diabetic E4LDLR
diabetic E3LDLR-/- (white triangles) and diabetic E4LDLR
group.  B: Fasting plasma insulin, as determined by ELISA. (* 
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A: Fasting plasma glucose of non-diabetic E3LDLR
-/- (black squares) mice, and following injection of STZ in 
-/- (black triangles) mice.
P < 0.05, ** P < 0.01)      
  
-/- (white 
 n =  8-12 per 
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E3LDLR-/- E4LDLR-/- Diabetic E3LDLR-/- Diabetic E4LDLR-/- 
Body Weight (g) 29.5 ± 0.9 30.2 ± 1.3 23.9 ± 0.9 † 24.6 ± 1.0 † 
Total Cholesterol (mg/dl) 338.5 ± 14.4 372.4 ± 42.7 449.7 ± 46.7 795.9 ± 56.4 * † 
Total Triglycerides (mg/dl) 296.9 ± 24.7 311.2 ± 26.5 431.8 ± 56.3 624.8 ± 48.1 * † 
Free Fatty Acids (mmol) 0.92 ± 0.09 0.91 ± 0.10 1.16 ± 0.08 1.47 ± 0.05 * † 
     
Glucose (mg/dl) 146.3 ± 6.1 151.3 ± 4.9 470.8 ± 16.3 † 479.3 ± 21.4 † 
Insulin (ng/ml) 0.42 ± 0.07 0.48 ± 0.12 0.01 ± 0.01 † 0.03 ± 0.01 † 
Ketone Bodies (µmol/L) 87.8 ± 27.4 122.5 ± 16.7 231.0 ± 43.9 † 244.5 ± 49.7 † 
Lipoprotein AGEs (µg/ml) 2.02 1.95 2.30 2.38 
     
Food Consumed (g/day) # 4.8 ± 0.7 5.7 ± 1.1 11.9 ± 1.3 † 12.6 ± 1.9 † 
Urine Excretion (ml/day) # 2.0 ± 0.2 1.7 ± 0.2 13.8 ± 0.5 † 13.6 ± 0.3 † 
 
 
Table 2.1.  Metabolic parameters of LDLR-/- mice expressing human apoE3 or apoE4.  For the 
“Diabetic” groups, measurements were taken 3 months after STZ treatment.  Data are means ± SD.  
* P > 0.05, genotype effect.  † P > 0.05 treatment effect.  n = 8-18 per group.  # n = 4-5 per group.      
  
  
 
Figure 2.2.  Plasma lipids and lipoprotein profiles. 
triglycerides (B) following a 4 hour fast. 
separated into lipoprotein fractions by FPLC. Lipoprotein cholesterol (C) and triglyceride (D) 
profiles of non-diabetic E3LDLR
squares).  E-F:  Lipoprotein cholesterol (E
(white triangles) and diabetic E4LDLR
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A-B:  Total plasma cholesterol (A) and 
n = 8-18. C-D:  Pooled (n = 6-8) plasma samples were 
-/- (white squares) and non-diabetic E4LDLR-/- 
) and triglyceride (F) profiles of diabetic E3LDLR
-/- mice (black triangles). (* P < 0.05, ** P
mice (black 
-/- 
 < 0.01)         
  
 
 
Figure 2.3.  Lipoprotein lipid composition and apolipoprotein distribution.  A:  VLDL distributio
of cholesterol, triglycerides, and phospholipids. B
sequential ultracentrifugation from 800 µl pooled (n = 6) plasma.  F
individual diabetic E3LDLR-/- (F) and diabetic E4LDLR
analyzed by 4-20% SDS-PAGE. 
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-E: Lipoprotein fractions were separated by 
-G:  Total plasma ApoA1 from 
-/- (G) mice. Apolipoproteins were 
n 
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Figure 2.4.  Apolipoprotein E distribution, ApoCIII/ApoE ratio and VLDL lipolysis.  A-B:  ApoE 
protein was determined by ELISA in lipoprotein fractions separated by FPLC from the pooled 
plasma (n = 6) of diabetic E3LDLR-/- (A) and diabetic E4LDLR-/- (B) mice.  C:  Plasma 
Apolipoprotein CIII and Apolipoprotein E protein was measured by ELISA.  n = 4-8.  Data is 
expressed as the ratio of ApoCIII/ApoE relative to the mean of non-diabetic E3LDLR-/- mice as 
1.0.  D:  VLDL was isolated from diabetic E3LDLR-/- (white triangles) or diabetic E4LDLR-/- 
(black triangles) mice and incubated at 37°C with bovine lipoprotein lipase. The reaction was 
stopped at timepoints indicated by adding 5M NaCl, and FFA release (FAtimepoint  - FA0) was 
measured. n = 4-6. 
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Lipoprotein clearance and post-prandial fat tolerance   
As the employed model lacks the LDLR, we measured the expression of several other 
genes involved in lipoprotein uptake. The expression of apoE, LRP1 (LDLR related protein 1), SR-
B1 (scavenger receptor B type 1) and NDST1 (N-deacetylase/N-sulfotransferase 1) did not differ 
significantly between the two diabetic groups, nor by induction of diabetes (Figure 2.5A).  Gene 
expression of VLDLR was increased approximately 8-fold by STZ treatment, but the difference 
between diabetic E3LDLR-/- and E4LDLR-/- mice was not significant. 
We next measured the efficiency of VLDL clearance in diabetic E3LDLR-/- and diabetic 
E4LDLR-/- mice by injecting VLDL isolated from ApoE deficient mice and labeled with DiI.  
There was no difference in the fractional catabolism of VLDL between the two diabetic groups 
(Figure 2.5B).  Similarly, there was no difference in the clearance of LDL particles isolated from 
non-diabetic LDLR-/- mice (Figure 2.5C).  We also examined whether or not the lipoprotein 
particles from diabetic mice with apoE3 or apoE4 are cleared differently by injecting non-diabetic 
LDLR-/- recipients of 125I-labeled VLDL or LDL isolated from diabetic E3LDLR-/- or diabetic 
E4LDLR-/- mice.  There was no difference in their clearance (Figure 2.6A and B). These data 
demonstrate that the clearance of VLDL remnants and LDL are not the major cause of the 
enhanced diabetic dislipidemia observed in E4LDLR-/- mice compared to E3LDLR-/- mice. 
Plasma triglyceride levels in the diabetic E4LDLR-/- mice dropped to similar levels in 
E3LDLR-/- mice after an overnight fast.  Following administration of an oral gavage of olive oil to 
the diabetic mice, however, plasma triglyceride levels of the E4LDLR-/- mice quickly re-
established a level two-fold higher than E3LDLR-/- mice and remained high at all points post-
gavage  (Figure 2.5D). Except for the initial increase, clearance appeared to be equally impaired in 
the two groups suggesting that diabetes is affecting postprandial lipid clearance equally.  Intestinal 
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absorption assessed by olive oil gavage after Tyloxapol injection did not differ by apoE genotype 
(Figure 2.7).   
 
VLDL secretion   
             Altered hepatic VLDL secretion is a possible contributing factor to the elevated plasma 
lipids in the diabetic E4LDLR-/- mice.  Thus, we measured plasma accumulation of triglycerides 
as a marker of VLDL secretion.  Following inhibition of VLDL uptake and lipolysis by injection of 
the detergent Tyloxapol, the triglyceride secretion rate in non-diabetic E3LDLR-/- and E4LDLR-/- 
mice was similar, averaging 3.2 ± 0.5 and 4.0 ± 0.4 mg/dl/min triglycerides, respectively (Figure 
2.5E).  The secretion rate in the diabetic E3LDLR-/- mice did not differ significantly from those of 
non-diabetic animals, averaging 3.5 ± 0.6 mg/dl/min triglycerides.  In contrast, the secretion rate in 
the diabetic E4LDLR-/- mice was significantly elevated; averaging 7.0 ± 0.5 mg/dl/min, reaching a 
mean plasma triglyceride level of 1431.3 ± 49.3 mg/dl two hours after Tyloxapol injection (Figure 
2.5E).   
 
 Figure 2.5.  Lipoprotein clearance and secretion.  
SR-B1, and NDST1. Data are expressed relative to non
clearance.  B: VLDL  and C: LDL clearance.  VLDL and LDL were isolated from plasma of 
APOE-/- mice and LDLR-/- mice, respectively,  labeled
E3LDLR-/- (white triangles) and diabetic E4LDLR
Post-prandial lipid tolerance. Plasma TG was measured in diabetic E3LDLR
and diabetic E4LDLR-/- mice (black traingles) following an oral gavage of olive oil after overnight 
fast. n = 6-8.  E:  VLDL secretion. Plasma triglycerides of non
squares), non-diabetic E4LDLR-/
diabetic E4LDLR-/- mice (black traingles) following injection of Tyloxapol. 
P < 0.05, ** P < 0.01) 
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A:  Liver mRNA levels of ApoE, LRP, VLDLR, 
-diabetic mice. n = 6-7.  B-
 with DiI and injected into diabetic 
-/- (black triangles) mice after a 4 hour fast.  
-/- (white triangles) 
-diabetic E3LDLR-
- (black squares), diabetic E3LDLR-/- (white triangles) and 
n = 4
C:  Lipoprotein 
D: 
/- (white 
-6 per group. (* 
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Figure 2.6.  Lipoprotein clearance.  A-B:  VLDL (A) or LDL (B) isolated from diabetic E3LDLR-
/- or diabetic E4LDLR-/- mice was labeled with 125I and re-injected via tail vein into non-diabetic 
LDLR-/- recipients.  Plasma was collected at the listed timepoints and measured for radioactivity. 
All values are normalized to values 2 minutes post-injection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7.  Dietary lipid absorption. Diabetic E3LDLR-/- (white triangles) and diabetic E4LDLR-
/- (black triangles) mice were given an oral gavage of olive oil (200 µl) 5 minutes after tail vein 
injection of Tyloxapol (0.7 mg/g BW).  Plasma triglycerides were measured 0, 30, 60, and 120 
minutes post-gavage. n = 3-4. 
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Energy usage, hepatic lipid stores and fatty acid metabolism 
             To assess global energy metabolism in the diabetic E3LDLR-/- and E4LDLR-/- mice, 
indirect calorimetry analysis was performed.  Diabetic E4LDLR-/- mice had significantly higher 
daily Respiratory Exchange Ratios (VCO2/VO2), particularly during the light cycle, than E3LDLR-
/- mice (Figure 2.8A-B).  This difference in RER was not due to altered activity (data not shown).  
A higher average RER in the diabetic LDLR-/- mice with E4 (0.915 ± 0.003) compared to those 
with E3 (0.896 ± 0.004, p<0.01) during the light cycle indicates that the presence of apoE4 results 
in a lower fractional reliance on lipid as an energy source. 
Non-diabetic E3LDLR-/- and E4LDLR-/- mice had similar triglyceride stores in the liver.  
Interestingly, diabetes induced a significant accumulation of hepatic triglycerides only in 
E4LDLR-/- mice, as they store twice as much as diabetic E3LDLR-/- mice (Figure 2.8C).  This 
increase was not sufficient to cause overt steatosis and there were no notable histological 
abnormalities in the livers of the diabetic mice (data not shown).  The increase in hepatic TG 
storage in E4LDLR-/- mice during diabetes was also associated with an increase in plasma free 
fatty acids (FFA) (Table 2.1). 
Diabetes increased hepatic gene expression of SREBP1c and FOXO1, regulators of 
lipogenesis and VLDL secretion, respectively.  Both tended to be higher in diabetic E4LDLR-/- 
mice compared to diabetic E3LDLR-/- mice, but the increase did not reach significance (Figure 
2.8D).  Expression of genes for SREBP2, ChREBP, PPARα and CPT1 did not alter significantly 
between the two genotypes.  Importantly, expression of fatty acid synthase (FASN) decreased 
significantly in E3LDLR-/- livers following STZ treatment, while remaining elevated in diabetic 
E4LDLR-/- livers (Figure 2.8D).  Although protein levels of AMP-activated protein kinase 
(AMPK) and phosphorylated AMPK (pAMPK) were similar, a significantly lower phosphorylated 
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Acetyl-CoA Carboxylase (pACC) / ACC ratio was noted in livers isolated from diabetic E4LDLR-
/- mice compared to E3LDLR-/- livers (Figure 2.8E-F).  Total ACC also tended to be lower, but 
did not reach significance.  A lower pACC/ACC ratio is indicative of decreased fatty acid 
oxidation and increased fatty acid synthesis.  Together, these data suggest that increased fatty acid 
synthesis and reduced fatty acid oxidation underlie an accumulation of lipid stores in the livers of 
diabetic E4LDLR-/- mice. 
 
  
  
Figure 2.8 . Calorimetry, hepatic TG storage and regulation of FA metabolism.  
exchange ratio (VCO2/VO2) was calculated over 48 hours in diabetic E3LDLR
E4LDLR-/- mice using indirect calorimetry. 
measured following homogenization and lipid extraction. 
SREBP1c, SREBP2, FOXO1, ChREBP, PPAR
E3LDLR-/- and diabetic E4LDLR
14.  E:  Livers from diabetic E3LDLR
protein expression of phosphorylated AMP kinase (pAMPK), total AMPK, phosphorylated acetyl
CoA carboxylase (pACC) and total ACC
Band intensity from (E) was quantitated using Image J software. Data is expressed relative to 
diabetic E3LDLR-/- in Arbitrary Units (A.U.). 
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A
-/-
n = 4.  C:  Hepatic TG content. Liver TG was 
n = 6-8.  D:  Gene expression of 
α, CPT1 and FASN in the livers of diabetic 
-/- mice. Data are expressed relative to non-diabetic mice. 
-/- and diabetic E4LDLR-/- mice were homogenized and 
 was determined by Western blot analysis. 
      
-B:  Respiratory 
 and diabetic 
n = 8-
-
n = 4.  F:  
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Glucose and lipid metabolism in primary hepatocytes   
             To verify a decrease in fatty acid oxidation in the livers of diabetic E4LDLR-/- mice, 
primary hepatocytes were isolated and cultured for 72 hours in high (25 mM) glucose medium to 
mimic the hyperglycemic environment of diabetes. Control cells were incubated in low glucose (5 
mM) for the same period.  Similar to the triglyceride accumulation noted in the liver in vivo, 
primary hepatocytes harvested from E4LDLR-/- mice and cultured in high glucose accumulated 
more lipid than E3LDLR-/- cells (Figure 2.9A-B).   The total area of lipid per cell was 2-fold 
higher in cells expressing E4 than E3 (16.6 ± 1.9 and 7.7 ± 0.6 µm2 / cell, respectively) (Figure 
2.9B). 
FFA uptake, measured using 14C-Palmitic acid, increased in hepatocytes cultured in the 
high glucose medium, but was not affected by ApoE isoform (Figure 2.9C).  Similarly, there was 
no ApoE isoform effect on the cellular uptake of glucose (Figure 2.9D).  The rate of de novo 
lipogenesis (DNL), defined here as 14C incorporation into the lipid layer in cells cultured in the 
presence of 14C-Glucose, was higher in hepatocytes cultured in high glucose medium than those 
cultured in low glucose medium.  However, hepatocytes isolated from E3LDLR-/-and E4LDLR-/- 
mice did not differ in their rate of DNL in either the low or high glucose environment (Figure 
2.9E). 
We next examined the rates of glucose and lipid oxidation in the E3LDLR-/- and E4LDLR-
/- hepatocytes.  Three days in high glucose medium decreased rates of 14C-glucose oxidation in 
both E3LDLR-/- and E4LDLR-/- hepatocytes.  However, there was no significant difference in 
glucose utilization between them (Figure 2.9F).  Finally, we measured lipid oxidation in primary 
hepatocytes cultured in high or low glucose using 14C-Palmitic acid.  E3LDLR-/- and E4LDLR-/- 
hepatocytes cultured in the low glucose media demonstrated similar rates of lipid oxidation.  When 
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cultured in the high glucose environment, however, there was a striking down-regulation of lipid 
oxidation only in E4LDLR-/- hepatocytes (Figure 2.9G).  After 72 hours in the high glucose 
condition, the E4LDLR-/- hepatocytes had lipid oxidation rates approximately 40% of those in the 
E3LDLR-/- hepatocytes.  
 
  
 Figure 2.9.  Metabolic Analyses of Primary 
/- or E4LDLR-/- mice were cultured for 72 hours in high glucose (HG, 25 mM) media and stained 
with Oil Red O to highlight lipid droplets.  
measuring 50 randomly chosen cells from 4 separate cultures per group.  
estimated by counting intracellular radiation after incubating hepatocytes for 1 min with 2 µCi/ml 
14C-Palmitate.  D:  Glucose uptake was measured following a 10 min incu
2-deoxyglucose after starving cells for 2 hours.  
radiation in the lipid layer after 24 hour incubation with 
Glucose (G) and 14C-Palmitate (H) was
using a customized self-contained CO
0.05, ** P < 0.01)     
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Hepatocytes.  A:  Primary hepatocytes from E3LDLR
B: Total lipid droplet area per cell was quantified by 
C:  Fatty acid uptake was 
bation with 1 µCi/ml 
E:  de novo lipogenesis was measured by counting 
14C-Glucose.  F-G:  Oxidation of 
 measured by trapping 14CO2 during a 3 hour incubation 
2 trap. n = 4-12 wells per trial, 3 trials per group.  (* 
-
3H-
14C-
P < 
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Diabetic atherosclerosis    
             Reflecting their severe dyslipidemia, diabetic LDLR-/- mice carrying the E4 allele had 
aortic plaques on average 3-fold greater in area than those with E3 (Figure 2.10).  The size of the 
atherosclerotic plaques in diabetic E4LDLR-/- mice (141,000 ± 19,000 µm2) was significantly 
greater when compared to diabetic E3LDLR-/- mice (48,000 ± 9,000 µm2)  as well as to both non-
diabetic E3LDLR-/- and non-diabetic E4LDLR-/- mice (32,000 ± 8,000 and 40,000 ± 12,000 µm2) 
(Figure 2.10).   While diabetic E4LDLR-/- mice had larger and more complex atherosclerotic 
lesions than diabetic E3LDLR-/- mice, the number of macrophages (Figure 2.11A-B) and 
apoptotic cells (Figure 2.11C-D) per lesion area were similar between the two groups. 
 
  
  
Figure 2.10. Atherosclerosis  at the aortic root.  
with H&E and Oil Red O.  Photos are representative of the mean plaque size of non
E3LDLR-/- (A), non-diabetic E4LDLR
mice (D).  E:  Data points represe
the aortic root.  n = 9-12 per group. (* 
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A-D:  Cross sections of the aortic root were stained 
-/- (B), diabetic E3LDLR-/- (C), and diabetic E4LDLR
nt the average lesion area of four distinct histological sections of 
P < 0.05, ** P < 0.01)        
-diabetic 
-/- 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11. Apoptosis and macrophage infiltration in the atherosclerotic plaque.
Macrophages were detected using MOMA
Cy5.  Plaques from diabetic E3LDLR
Brightfield (upper image) and Cy5 (blue, lower image). Magnifications are
fragmentation was detected in 8 µm frozen sections of the aortic root using ApopTag Fluorescein 
in situ staining.  Pictured are plaques bordering the aortic valves (V
of the image) of diabetic E3LDLR
solution was used to delineate ultrastructure. Magnifications are 30x.
 
 63
  
-2 antibodies followed by a secondary conjugated to 
-/- (A) and diabetic E4LDLR-/- (B) mice are shown in 
 20X.  C
-shaped structures at the center 
-/- (C) and diabetic E4LDLR-/- (D) mice.  A 1% methyl
 
A-B:  
-D:  DNA 
-green 
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2.5 Discussion 
 
              In the present work, we explored the isoform specific role of apoE in diabetic 
dyslipidemia utilizing diabetic LDLR-/- mice with human apoE4 or apoE3.  We found that:  1) 
Non-diabetic E3LDLR-/- and E4LDLR-/- mice are indistinguishable in all parameters of glucose 
and lipid metabolism measured in this study.   2) After induction of diabetes, E4LDLR-/- mice, but 
not E3LDLR-/-, develop enhanced dyslipidemia, characterized by elevated VLDL TG and LDL 
cholesterol, delayed clearance of post-prandial triglycerides, and an increased rate of VLDL 
secretion.  3) The severe dyslipidemia in diabetic E4LDLR-/- mice is associated with a larger 
hepatic lipid stores and a calorimetric profile suggestive of lower lipid utilization.  4) Primary 
hepatocytes isolated from E4LDLR-/- mice and cultured in high glucose accumulated more 
intracellular lipid concomitant with a reduction in fatty acid oxidation.  5) Finally, these metabolic 
disturbances during diabetes culminated in exaggerated atherosclerosis only in E4LDLR-/- mice.  
           Diabetic dyslipidemia in poorly treated type 1 diabetes and type 2 diabetes share many 
features (2).  In many patients with diabetes, the levels of circulating lipoproteins during fasting are 
relatively normal (21).  Instead, the major impairments to lipoprotein metabolism occur with their 
ability to clear post-prandial lipoproteins (2).  The prolonged elevation of plasma triglycerides 
following a fatty meal has been demonstrated in individuals carrying the E4 allele (6), and our 
previous work demonstrated post-prandial lipemia in LDLR over-expressing mice with human 
apoE4 (22).   Higher post-prandial triglycerides in the diabetic E4LDLR-/- mice suggest an 
interaction between apoE4 and hyperglycemia that elicits a delay in the clearance of chylomicron 
remnants through non-LDLR mediated pathways.  Previously, Goldberg et al showed that STZ-
induced diabetic LDLR-/- mice accumulated a “subclass of lipoproteins” that normally are quickly 
removed from the circulation (23).  Our experiments confirmed that postprandial lipid clearance is 
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impaired in diabetic LDLR-/- mice.  However, except for the initial increase in plasma triglyceride 
in E4LDLR-/- mice, the postprandial clearance rate was not different between the two groups.  In 
addition, we found no APOE genotype effect on the fractional catabolism of either VLDL or LDL.  
         VLDL production is increased in type 2 diabetes and in uncontrolled type 1 diabetes (2).  In 
insulin-resistant patients, this increased VLDL production is oftentimes part of a dyslipidemic 
cycle, in which larger adipose tissue stores are associated with increased FFA release (24).  In turn, 
an increased flux of FFA to the liver stimulates VLDL secretion (25).  The FFA-stimulated VLDL 
production is compounded in an insulin-resistant or insulin-deficient state (2).  Along these lines, 
the increased plasma VLDL in the diabetic E4LDLR-/- mice is accompanied by a 2-fold increase 
in TG secretion.  In comparison, TG secretion in the diabetic E3LDLR-/- mice was not different 
from that in the non-diabetic controls. Similarly, LDLR-/- mice expressing murine apoE do not 
have increased rates of TG production following STZ-induced diabetes (23).  We note that 
increased hepatic secretion of TG-rich particles is most likely responsible for the majority of LDL-
sized particles in E4LDLR-/- mice, since absence of LDLR has been shown to result in 
overproduction of TG-rich particles smaller than normal VLDL (26,27).  Thus, the dyslipidemic 
cycle commonly seen in patients with insulin-resistance is reflected by the insulin-deficient 
E4LDLR-/- mice employed in this study, which have higher circulating FFA, larger hepatic TG 
stores and higher rates of TG secretion than diabetic E3LDLR-/- mice.   
Indirect calorimetry analysis revealed a clear apoE genotype effect on energy usage during 
diabetes at the whole body level.  Diabetic E4LDLR-/- mice had significantly higher RER, 
demonstrating a lower ratio of lipid to carbohydrate oxidation compared to diabetic E3LDLR-/- 
mice during the light cycle.  This reduced reliance on lipid oxidation appears to be central to the 
liver and directed by ACC signaling.  When active, ACC catalyzes the production of malonyl-
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CoA, thereby stimulating lipogenesis and inhibiting the beta-oxidation of fatty acids (28).  A 
significant reduction in the pACC/ACC ratio in the livers of diabetic E4LDLR-/- mice indicates an 
increase in lipogenesis and decrease in fatty acid oxidation.  In addition, STZ treatment decreased 
FASN gene expression in the E3LDLR-/- mice, as previously reported in wild type mice (29).  
However, this diabetes-induced reduction did not occur in E4LDLR-/- mice, suggesting a higher 
rate of fatty acid synthesis in these mice.  Higher expression of FASN was not due to stimulation 
by ChREBP.  Expression of SREBP1c, an important regulator of FASN-directed lipogenesis, on 
the other hand, tended to be higher in the diabetic E4LDLR-/- livers but did not reach significance.  
Regardless, these data point toward two distinct means (metabolically linked by ACC signaling) by 
which lipid accumulates in the E4LDLR-/- livers during diabetes – an increase in fatty acid 
synthesis and a reduction in fatty acid oxidation.  Consistent with this data, apoE4 expressing 
LDLR-/- hepatocytes cultured in high glucose reduced their rate of lipid oxidation to levels 
approximately 40% of that in E3LDLR-/- hepatocytes and amassed more than twice as much lipid. 
LDLR-/- mice are an established model for a high fat diet induced obesity and insulin 
resistance, and we have previously shown that mice expressing apoE4 are more susceptible to diet-
induced glucose intolerance than those expressing apoE3 (30).  This propensity of apoE4 
expressing mice to develop glucose intolerance likely contributes to the impaired lipid metabolism 
in the insulin deficient state.  In this context, we note that VLDLR mRNA was significantly 
increased after the STZ treatment and the mRNA levels tended to be higher in the diabetic 
E4LDLR-/- livers than in the diabetic E3LDLR-/- livers.  While the contribution of VLDLR in 
hepatic remnant clearance during diabetes is not clear, fasting hypertriglyceridemia in VLDLR-/- 
mice has been previously noted (31) and when over-expressed in the liver, VLDLR appears to 
function similarly to LDLR and LRP (32).  The VLDLR plays an important role in adipocyte TG 
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accumulation (33), and could be a potential player in the process of hepatic lipid accumulation 
during diabetes. 
Our results support the possibility that apoE functions as a metabolic signaling molecule 
outside its established role in lipoprotein clearance.  For example, a role for apoE as a signaling 
molecule has been shown previously in the context of Alzheimer’s disease (34), where it has been 
shown to affect activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-
terminal kinase (JNK) in an apoE isoform specific manner (35).  Similar apoE4-specific signaling 
could account for some of the metabolic abnormalities during diabetes highlighted in this study.  
Alternatively, apoE has been shown to enhance VLDL secretion (36), as well as play a role in the 
accumulation of lipid in early and intermediary secretory compartments of hepatocytes (37).  Thus, 
inefficient recycling and re-secretion of apoE4 (38), could potentially affect the availability, 
packaging, and/or transport of TG from the hepatic lipid pool.  Irrespective of the precise mode of 
action, our results demonstrate a possible chain of events in diabetic E4LDLR-/- livers: a down-
regulation of lipid oxidation and up-regulation of fatty acid synthesis lead to larger hepatic 
triglyceride stores which in turn drive an increase in VLDL secretion. Combined with marked 
diabetic effects which impair VLDL and post-prandial TG clearance, these processes are ultimately 
responsible for the severe dyslipidemia observed in the diabetic E4LDLR-/- mice.  
Importantly, the diabetes-induced acceleration of atherosclerosis occurs only in LDLR-/- mice 
expressing apoE4.  Previous studies of the STZ-induced diabetes in LDLR-/- mice have produced 
variable results, with some groups showing an increase in atherosclerosis (39, 40), while others 
show no change (41, 42).  Although the reasons for these mixed results are unknown, varying 
experimental conditions, such as diet, could contribute (43).  The E4-specific acceleration of 
atherosclerosis is likely a direct result of the severe dyslipidemia brought about by STZ-induced 
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diabetes in these mice, although contributions of other factors, such as apoE4 specific effects on 
macrophages, cannot be excluded (44).  Regardless, our data clearly demonstrates the presence of 
E4 effects that are independent of the LDLR.  Moreover, the exaggerated dyslipidemia and 
atherosclerosis observed in the diabetic E4LDLR-/- mice extends beyond the scope of type 1 
diabetes and has implications for the growing number of apoE4 carriers with insulin resistance and 
type 2 diabetes.  In conclusion, the apoE4-specific atherosclerosis and diabetic dyslipidemia 
illustrated in this study may also play an important role in patients with diabetes who carry the 
apoE4 isoform.     
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A NOVEL, NORMOLIPODEMIC MOUSE MODEL OF DIABETIC ATHEROSCLEROSIS:  
DIABETIC ‘AKITA’ MICE EXPRESSING HUMAN APOE4 AND INCREASED LDLR 
DEVELOP ATHEROSCLEROSIS WITHOUT SEVERE HYPERCHOLESTEROLEMIA 
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3.1 Introduction 
 
        The leading cause of mortality among patients with diabetes is cardiovascular disease (CVD), 
including enhanced atherosclerosis (1-4).  Cardiovascular related mortality in patients with 
diabetes is two to four times higher than normoglycemic patients and consequently, diabetes is 
regarded as a coronary heart disease (CHD) risk equivalent (5-6).  Current estimates by the Center 
for Disease Control indicate that approximately 11% of the US adult population has diabetes (6). 
        Diabetic dyslipidemia, a common cluster of harmful changes to lipoprotein metabolism, is an 
important contributor to the progression of atherosclerosis (7) and lowering cholesterol levels in 
patients with diabetes reduces CHD risk (5).  However, even with a reduction in CHD risk 
achieved with robust cholesterol-lowering, the absolute CHD rates of patients with diabetes is still 
significantly higher than low-risk populations (5).  This suggests that cholesterol-independent 
effects of diabetes, such as inflammation and endothelial dysfunction are equally important. 
        However, past research has failed to adequately separate the effects of diabetes-induced 
dyslipidemia from the lipid-independent effects alluded to above, particularly in regards to animal 
models of disease (8-10).  This is because current mouse models of diabetic atherosclerosis all 
employ severely hyperlipidemic models, most in which hyperlipidemia becomes more severe upon 
induction of diabetes.  For instance, in human patients total serum cholesterol values <200 mg/dl 
are considered “Desirable” and >240 mg/dl are considered “High” under current clinical guidelines 
(5).   Even the 95th percentile of patients aged 20 or older have average cholesterol levels of 318 
mg/dl for men and 273 mg/dl for women.  In contrast, mouse models of atherosclerosis such as 
apolipoprotein E (apoE) deficient mice, typically have cholesterol values ranging from 400-1000 
mg/dl (11-21), and can go as high as 1715 mg/dl during diabetes (22).  In these diabetic models, 
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the consequent hyperlipidemia, rather than the diabetes itself, is likely the major cause of increased 
atherosclerosis (7-10). 
      Apolipoprotein E (apoE) is a small circulating protein associated predominantly with VLDL 
and HDL, and is the primary ligand for the LDLR, making it a crucial component in the clearance 
of lipid from the circulation and a major determinant of plasma cholesterol and CVD risk (23).  
The APOE gene is polymorphic, producing three common isoforms: apoE2, apoE3, and apoE4.  
The apoE4 isoform is associated with higher LDL cholesterol and an increased risk of CVD (23).    
      In this study, we employ “E4h” mice that are homozygous for replacement of the endogenous 
mouse APOE gene with the human APOE*4 (E4) allele and heterozygous for an allele that 
overexpresses the human LDL receptor (h).  When fed a high fat/high cholesterol diet, E4h mice 
accumulate cholesterol-rich VLDL remnants, have reduced HDL, and develop atherosclerosis (24).  
Here, we describe the generation of distinct atherosclerotic plaques when E4h mice are made 
diabetic by the Ins2+/- “Akita” mutation, a genetic model of type 1 diabetes (25).  Diabetic E4h 
mice develop atherosclerosis despite plasma cholesterol within a normal range (<175 mg/dl).   
       To our knowledge, E4h Akita mice represent the first mouse model in which:  1) diabetes is 
required for atherosclerosis development, 2) atherosclerosis occurs spontaneously on normal chow 
diet low in cholesterol, 3) no important components of lipoprotein metabolism such as apoE or 
LDLr are missing, and most importantly 4) atherosclerotic plaques develop in the absence of 
severe hyperlipidemia.  This unique model highlights the importance of distinct lipoprotein profiles 
rather than only total plasma lipids, and will enable future research to more accurately address the 
patient-research model discrepancies in the background of diabetes.   
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3.2 Methods 
 
Mice and induction of diabetes.  Mice homozygous for replacement of the endogenous Apoe 
gene with the human APOE*3 (E3) or human APOE*4 (E4) allele (26-27) were crossed with mice 
heterozygous for the Ins2+/- “Akita” mutation (25) and/or with mice heterozygous for a targeted 
replacement of the mouse Ldlr gene with the stabilized human Ldlr minigene (Ldlrh/+) (24, 28).  
All mice were on C57BL/6 backgrounds.  Male mice were fed normal chow diet ad libitum (5.3% 
fat and 0.02% cholesterol) (Prolab IsoPro RMH 3000; Agway Inc).  Biochemical analyses were 
carried out at 6 months of age unless otherwise stated. Animals were handled under protocols 
approved by the Institutional Animal Care and Use Committees of the University of North 
Carolina. 
 
Biochemical assays.  After a 4 hour fast, animals were anesthetized with 2,2,2-tribromoethanol 
and blood was collected. Plasma glucose, cholesterol, phospholipids and ketone bodies were 
measured using commercial kits (Wako). Triglycerides and insulin were determined using 
commercial kits from Stanbio and Crystal Chem Inc., respectively.  Lipoprotein distribution and 
composition was determined with pooled (n=5-6) plasma samples (100 µl) fractionated by fast 
protein liquid chromatography (FPLC) using a Superose 6 HR10/30 column (GE Healthcare).  
Pooled plasma (250 µl) was separated by sequential density ultracentrifugation (UC) into density 
fractions ranging from <1.006 g/ml (VLDL) to >1.21 g/ml (HDL) and subjected to electrophoresis 
in a 4-20% denaturing SDS-polyacrylamide gel (29).  For VLDL secretion, plasma TG was 
measured following injection of Tyloxapol (Triton WR-1339; Sigma ) via tail vein (0.7 mg/g BW) 
after a 4 hour fast (8).  ApoB content was determined in pooled (n = 6) plasma samples following 
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UC at <1.006 g/ml by western blot using 1:2000 dilution of α-apoB primary antibody (Abcam) and 
1:10,000 dilution of α-Rb HRP-conjugated secondary antibody (Cell Signaling).   
 
Peritoneal macrophage isolation.  Macrophages were isolated from the peritoneal cavity 4 days 
after intraperitoneal injection of 0.5 ml of 4% (w/v) thioglycolate (BD Biosciences).  Cells used for 
gene expression analysis were collected directly and stored at -20° C until measurement.  
Macrophages employed for in vitro analyses were washed with Ham’s nutrient mixture F-10 
medium, spun at 1000 x g for 5 minutes, plated in 12-well plates at a density of 5 x 105 cells/well, 
and cultured in 5 mM (Low) or 25 mM (High) glucose media supplemented with 5% fetal bovine 
serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine.  Cells were 
washed 2 hours later to remove non-adherent cells. 
 
Atherosclerosis.  After 3 months of diabetes, mice were euthanized with a lethal dose of 2,2,2-
tribromoethanol and perfused at physiological pressure with 4% phosphate buffered 
paraformaldehyde (pH 7.4).  Morphometric analysis of plaque size at the aortic root was performed 
as described (32). 
 
 
3.3 Results 
 
Plasma glucose and lipids 
      While there was no APOE genotype effect on fasting plasma glucose in the non-diabetic 
groups, there was a significant reduction in fasting plasma glucose in mice overexpressing LDLR 
  78
(Figure 3.1A, left side).  All four diabetic groups, regardless of LDLR expression or APOE 
genotype, had fasting plasma glucose exceeding 400 mg/dl (Figure 3.1A, right side).  Diabetic 
mice expressing E4 have higher fasting plasma glucose than diabetic mice with E3, and glucose 
was higher in diabetic E4h mice compared to diabetic E4 mice, but neither trend reached statistical 
significance.  Conversely, fasting plasma glucose was significantly higher in diabetic E4h mice 
compared to diabetic E3h mice (Figure 3.1A, far right). 
       There were no significant differences in fasting plasma triglycerides between any of the 
diabetic or non-diabetic groups.  There was also no effect of APOE genotype, diabetes or LDLR 
expression on fasting plasma free fatty acids in any experimental group (Table 3.1). 
       Increased expression of the LDLR led to decreased plasma total cholesterol in the non-diabetic 
mice regardless of APOE genotype (Figure 3.1B, left side).  In contrast, the effect of increased 
LDLR expression was not present when mice were diabetic.  In addition, there was no significant 
change in total plasma cholesterol upon induction of diabetes in mice expressing E3 (Figure 3.1B, 
white bars).  However, when mice expressing E4 were made diabetic there was a significant 
increase in total plasma choleseterol regardless of LDLR expression (Figure 3.1B, black bars).   
Taken together, these data demonstrate that diabetic mice expressing human apoE4 have higher 
plasma glucose and total cholesterol than non-diabetic mice as well as diabetic mice expressing 
human apoE3. 
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Figure 3.1.  Plasma glucose and cholesterol.  Plasma glucose (A) and total cholesterol (B) was 
measured in 4 month old non-diabetic and diabetic mice following a 4 hour fast. * p<0.05, 
**p<0.001. n = 5-10. 
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Table 3.1.  Metabolic paramaters of E3, E4, E3h and E4h mice.  Fasting plasma triglycerides, 
free fatty acids, insulin, and non-HDL to HDL cholesterol ratio.  
  
 Non-diabetic Diabetic 
E3 E4 E3h E4h E3 E4 E3h E4h 
Triglycerides 
(mg/dl) 
64.6  ± 
3.7 
67.6  ± 
3.1 
67.6  ± 
9.8 
55.6  ± 
6.4 
70.8  ± 
5.3 
75.2  ± 
4.9 
65.6  ± 
7.4 
58.2  ± 
7.5 
Free Fatty 
Acids (mmol) 
0.71 ± 
0.05 
0.74 ± 
0.08 
0.66 ± 
0.05 
0.70 ± 
0.14 
0.69 ± 
0.05 
0.84 ± 
0.11 
0.74 ± 
0.06 
0.70 ± 
0.12 
Insulin 
(pg/ml) 
n.d. 
960.0 ± 
93.2 
n.d. 
974.8 ± 
27.3 
n.d. 
128.2 ± 
90.8 
n.d. 
123.6 ± 
46.3 
Non-HDL / 
HDL  ratio 
(cholesterol) 
0.71 0.45 1.35 0.78 1.10 0.71 1.82 3.05 
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Lipoprotein distribution  
          We next examined the distribution of cholesterol among various lipoprotein fractions.  
Separating lipoprotein classes by size-exclusion using Fast Performance Lilquid Chromatography 
(FPLC) revealed that non-diabetic E3 and E4 mice carry the majority of their cholesterol in the 
form of HDL and that increasing LDLR levels resulted in a slight reduction in HDL cholesterol 
(Figure 3.2A-B).   
      With the exception of a small decrease in diabetic E3 mice compared to their non-diabetic 
counterparts, diabetes did not change the levels of HDL cholesterol.  However, VLDL and VLDL 
remnants were increased in all groups.  Interestingly, this increase was magnified in the diabetic 
E4h mice.  Thus, although plasma total cholesterol between diabetic E4 and E4h mice was 
indistinguishable, there is a dramatic shift in the lipoprotein profile.  Cholesterol in diabetic E4 
mice was primarily in HDL fractions while cholesterol in diabetic E4h mice is primarily in VLDL 
and VLDL remnant fractions (Figure 3.2D). 
      Consequently, the ratio of non-HDL cholesterol to HDL cholesterol, an atherogenic risk factor, 
was much higher in diabetic E4h mice than in the other groups (Table 3.1).   The shift towards an 
atherogenic pattern of cholesterol distribution in diabetic E4h mice was mirrored in density 
fractions separated by ultracentrifugation (Figure 3.3A-B).  The majority of cholesterol in the non-
diabetic and diabetic E4 mice was concentrated in HDL density fractions of 1.10 and >1.21 mg/dl 
(Figure 3.4A-B, white bars).  In contrast, the majority of plasma cholesterol in diabetic E4h mice 
was found in the VLDL and IDL fractions of <1.006 and 1.02 mg/dl (Figure 3.3B, black bars).   
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Figure 3.2.  Lipoprotein profiles.  Pooled plasma (100 µl) from non-diabetic E3 and E3h (A), 
non-diabetic E4 and E4h (B), diabetic E3 and E3h (C), and diabetic E4 and E4h (D) mice was 
separated on a Fast Performance Liquid Chromatography (FPLC) column and fractions were 
analyzed for cholesterol.  n = 6-8, pooled.  
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Figure 3.3.  Cholesterol and apolipoprotein distribution.   Pooled plasma (800 µl, n = 6) was 
separated into density fractions ranging from <1.006 to >1.21 mg/dl by ultracentrifugation.  A:  
Cholesterol distribution among the various density fractions in plasma from E4 (white bars) and 
E4h (black bars).  B:  Cholesterol distribution in diabetic E4 (white bars) and diabetic E4h (black 
bars) mice.  C-D: ApoB48 and apoE in the VLDL and IDL fractions of <1.006 and 1.02 mg/dl (C) 
and apoA1 in the HDL fractions of 1.10 and >1.21 mg/dl (D) was determined by SDS PAGE 
analysis. WM= weight marker. 
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Apolipoprotein distribution 
       In order to determine the apolipoprotein composition of the diabetic E4 and diabetic E4h mice, 
ultracentrifugation density fractions were submitted to SDS PAGE analysis.  Fasting plasma 
protein levels of apoB100 were undetectable in all groups, and little to no apoB48 was observed in 
the VLDL/IDL fractions of <1.006 and 1.02 mg/dl in the non-diabetic E4 and E4h mice.  There 
was a similar amount of apoB48 between the diabetic E4 and diabetic E4h mice, indicating that the 
number of VLDL remnants in these mice is similar (Figure 3.3C).   However, there was a clear 
reduction in apoE in these same fractions (Figure 3.3C).  This result indicates that the VLDL 
remnants in diabetic E4h mice are not only cholesterol enriched, but are also apoE poor.  In 
addition, in the density fractions of 1.10 and >1.21 mg/dl, there was a dramatic decrease in the 
HDL associated protein apoA1 in the diabetic E4h mice (Figure 3.3D).  
 
VLDL Secretion 
       Reduced insulin is associated with increased VLDL secretion (33).  The rate of hepatic VLDL 
secretion was estimated by injecting diabetic E4 and diabetic E4h mice with the detergent 
Tyloxapol which inhibits particle uptake and lipolysis.  The rate of TG accumulation in the plasma 
following Tyloxapol injection was similar between the two groups for the first 30 minutes post-
injection, but slowed significantly in diabetic E4h mice compared to diabetic E4 mice at 1 and 2 
hours (Figure 3.4A).   However, the accumulation of plasma cholesterol following injection was 
identical in both groups (Figure 3.4B).   
      To estimate the number of lipoprotein particles being secreted, we measured the amount of 
apoB in pooled samples (>1.006 mg/dl fraction) at 2, 60 and 120 minutes post-tyloxapol injection.  
The secretion of total apoB protein was similar between diabetic E4 and diabetic E4h mice, and the 
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amount of apoB48 secreted relative to apoB100 was higher in the diabetic E4h mice compared to 
the diabetic E4 mice (Figure 3.4C-E).  Together, these data suggest that during times of fasting, the 
diabetic E4h mice secrete primarily B48-containing, cholesterol-rich VLDL. 
 
Inflammation and macrophage LDL uptake 
       To determine the contribution of an inflammatory state on atherosclerosis development, 
several plasma markers of inflammation were measured in diabetic E4 and diabetic E4h mice.  
Measurable Interleukin 6 (IL-6) protein concentrations in the plasma of 6 month old was severely 
elevated in 3/11 diabetic E4h mice but was only modestly detectable in 1/8 diabetic E4 mice 
(Figure 5A, left side).  Similarly, measurable monocyte chemotaxic protein 1 (MCP-1) 
concentrations was detected in 5/11 diabetic E4h mice, compared to only 1/7 mice in the diabetic 
E4 mice (Figure 3.5B, right side).  Concentrations of circulating TNF-α were below the detectable 
range (<9 pg/ml) for all samples measured (data not shown). 
       We next examined whether apoE4 and the LDLR interact in macrophages to effect LDL 
uptake, and thus foam cell and atherosclerotic plaque formation.  DiI-labeled LDL uptake was 
measured in vitro using peritoneal macrophages isolated from non-diabetic E4 and E4h mice.  
When cultured in low glucose, E4h macrophages took up more oxidized LDL compared to E4 
macrophages, but the increase did not reach significance.  However, when cultured in high glucose 
media for 48 hours, E4h macrophages took up significantly more oxidized LDL compared to E4 
macrophages (Figure 3.5C).  Together, these data suggests that in addition to diabetes-induced 
lipoprotein disturbances, increased inflammation and macrophage activity may contribute to the 
atherogenesis noted in the diabetic E4h mice. 
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Figure 3.4. VLDL secretion.  A-B:  Hepatic secretion of VLDL in diabetic E4 (white squares) and 
diabetic E4h (black squares) mice was estimated by measuring the accumulation of triglycerides 
(A) and cholesterol (B) following injection of the detergent Tyloxapol via the tail vein.  C:  ApoB 
was measured by western blot in pooled samples of VLDL (>1.006 g/ml density fractions) at 2, 60 
and 120 minutes post-injection.  D-E:  The amount of total apoB (D) and apoB48 and apoB100 (E) 
was quantified from (C) using Image J software. 
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Figure 3.5.  Inflammation and macrophage LDL uptake.  A-B:  Markers of inflammation.  
Plasma protein concentrations of IL-6 (A) and MCP-1 (B) were measured using a Luminex 
Milliplex Analyst system. C:  Peritoneal macrophages isolated from E4 (white bars) or E4h (black 
bars) mice were cultured in low (5 mM) or high glucose media (25 mM) for 48 hours before a 4 
hour incubation with DiI-labeled oxidized LDL. 
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Diabetes-Induced Atherosclerosis in E4h mice 
      No vessel damage or atherosclerosis was noted in either of the non-diabetic experimental 
groups at 6 months of age.  Likewise, none of the diabetic E3, diabetic E3h or diabetic E4 mice 
analyzed showed any visible signs of atherosclerosis or foam cell formation.  In marked contrast, 
of the eight experimental groups analyzed in this study, only the diabetic E4h mice developed 
atherosclerotic pathology.  In spite of very low total plasma cholesterol (<175 mg/dl) and despite 
similar total plasma cholesterol as diabetic E4 mice, all seven diabetic E4h mice that were analyzed 
at 6 months of age showed clear fatty depositions within sub-endothelial areas (Figure 3.6).  Foam 
cells were not only present on the luminal surface but were also present in medial smooth muscle 
layers in two of the seven mice (Figure 3.6C,E).  There was no correlation between total plasma 
cholesterol or glucose and atherosclerotic plaque size when individual diabetic E4h mice were 
compared (data not shown). 
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Figure 3.6.  Athersoclerosis.  Atherosclerotic lesions at the aortic root.  A-F:  At 6 months of age, 
diabetic E4h mice were sacrificed, perfused with 4% PFA and 8 µm sections of the aortic root 
were sectioned.  Sections were stained with H & E and Oil Red O to highlight lipid.  Fatty intimal 
depositions, foam cell formations and atherosclerotic plaques from individual diabetic E4h mice 
(A-F).  Magnification is listed in the bottom right hand corner of each image.   
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Discussion 
 
        Diabetes is a major, independent risk factor for several forms of CVD (5).  The increased 
CVD risk for patients with diabetes is a result of several interconnected factors, including 
inflammation, endothelial dysfunction, hypertension, and a pro-thrombotic state (34).   
Unfortunately, past research has often failed to adequately dissociate the atherogenic potential of 
these factors from the common process of diabetic dyslipidemia (9).  Diabetic dyslipidemia is a 
cluster of harmful changes to lipoprotein metabolism, including an increase in VLDL and a 
decrease in HDL cholesterol, which is commonly seen in patients with diabetes (7). 
      Many studies employing mouse models have been unable to demonstrate a diabetes-induced 
increase in atherosclerosis, including those using apoE-/- (35), Ldlr-/- (12), Ldlr +/- with high 
cholesterol (13), apoB transgenic (15), CETP transgenic (36), and apoA1-deficient mice (14).  
Although some mouse models have shown a diabetes-induced acceleration of atherosclerosis, it 
has been difficult to distinguish between effects due to exaggeration of plasma lipids from those of 
diabetes itself (9).  Furthermore, the vast majority of current mouse models of atherosclerosis have 
plasma cholesterol levels far higher than even the most extreme human patients.  For example, men 
deemed at risk for CVD have cholesterol levels >240 mg/dl, while those in the highest 5% of the 
population have and average cholesterol of 318 mg/dl (5).  In comparison, common mouse models 
have normal cholesterol levels between 500-1000 mg/dl and have been shown to reach as high as 
1715 mg/dl when diabetic (22).  In addition, clinical trials have clearly shown that while aggressive 
cholesterol lowering therapies result in a reduction of CVD risk, even when plasma cholesterol is 
lowered to an equivalent “non-diabetic level”, a patient with diabetes still has a significantly higher 
CVD risk (5).  This strongly suggests that other factors, such as the ones mentioned above, must be 
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considered.  Thus, generating a mouse model of atherosclerosis in which the atherogenic effect of 
diabetes is not clouded by severe hyperlipidemia has long been a goal for researchers. 
       Here, we describe a novel model of diabetic atherosclerosis – the diabetic E4h mouse – that 
develops spontaneous atherosclerotic plaques despite total cholesterol levels <175 mg/dl.  The 
major advantages of this model include:  1) No genetic deficiencies; the important components of 
lipoprotein metabolism that are deficient in common models of atherosclerosis are present, and 
moreover in human form (apoE and LDLR),  2) Genetic, gradual, inobtrusive model of type 1 
diabetes (‘Akita’ mutation); no toxic effects of diabetes inducers such as STZ or alloxan,  3) No 
high cholesterol, high fat, or cholate diet is necessary to induce atherosclerosis, and 4) Most 
importantly, atherosclerosis occurs in the absence of severe hyperlipidemia.   To our knowledge, 
the diabetic 4h mice represent the first normolipidemic mouse model in which diabetes is required 
for atherosclerosis development.   
      To induce diabetes, we employed the Akita mutation, a genetic model of type 1 diabetes.  The 
spontaneous Akita mutation, in the Ins2 gene, leads to improper folding of proinsulin and eventual 
β-cell death (25).  As a consequence, male Akita mice develop hypoinsulinemia and severe 
hyperglycemia beginning around one month of age (25).  In the hyperlipidemic apoE-/- model of 
atherosclerosis, introduction of the Akita mutation resulted in a twofold increase in non-HDL 
cholesterol and a threefold increase in atherosclerosis (37).  In this study, we aimed to examine the 
APOE isoform effect on diabetic atherosclerosis in the setting of a more physiologically relevant 
range of plasma lipids. 
       Total plasma cholesterol levels remain quite low in the diabetic E4h mice compared to other 
models of diabetic atherosclerosis, where it usually exceeds 500 mg/dl (11-22).  Thus, the fact that 
the diabetic E4h mice still develop distinct atherosclerotic plaques is a testament to the importance 
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of APOE isoform and its strong effect on the types of lipoproteins contributing to the total plasma 
cholesterol levels.   HDL cholesterol has been demonstrated to have the strongest effect on CVD 
risk in humans, and even in the presence of high LDL, can significantly decrease the risk of CHD 
(38).  Despite similar total cholesterol, the low HDL and high VLDL cholesterol in the diabetic 
E4h mice likely contributes to their atherogenesis, while the comparatively high HDL and low 
VLDL in the diabetic E4 mice is atheroprotective.    
      The LDLR has been shown to regulate hepatic VLDL production, with overexpression of 
LDLR leading to a decrease in apoB100 secretion (39).  Likewise, insulin has a well-established 
role as an inhibitor of hepatic VLDL secretion (33, 40).  In our study, the combination of 
hypoinsulinemia and overexpression of the LDLR in diabetic E4h mice led to a decrease in 
apoB100 secretion and the release of cholesterol-rich particles.  The similarity of the composition 
of lipoproteins that accumulate in the plasma with those that were characterized following 
tyloxapol injection, suggests that hepatic secretion of cholesterol-rich VLDL directly contributes to 
the atherogenic lipoprotein profile observed in these mice.  The accumulation of this cholesterol-
rich VLDL under normal conditions may be a direct result of the decrease in available apoE in the 
diabetic E4h mice. 
     Additionally, an inflammatory role for apoE has been previously suggested, with data 
demonstrating an increase in inflammation or a decrease in anti-inflammatory protection in the 
presence of apoE4 (41).   We have also shown that increasing LDLR expression in macrophages 
results in higher LDL uptake in the presence of apoE4 (30).  In addition, macrophages expressing 
apoE4 are less able to promote cholesterol efflux compared to those with apoE2 or apoE3 (30).  In 
our model of global LDLR overexpression, we noted a similar phenomenon in macrophages 
cultured in a high glucose environment, however only in the uptake of oxidized LDL. Interestingly, 
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this suggests a potential role for the LDLR in modulating the uptake of modified particles 
previously thought to be limited to scavenger receptors such as CD-36 (42). 
        In summary, the diabetic E4h model demonstrates an initiation of atherosclerosis in the 
absence of severe diabetes-induced hyperlipidemia (cholesterol levels <125 mg/dl).  With total 
cholesterol remaining <175 mg/dl, the diabetic E4h mice highlight the importance of lipoprotein 
cholesterol distribution, inflammation and macrophage activity on the development of 
atherosclerosis.  Plasma lipids in this model are within a physiological range that current mouse 
models fall far outside of, and imperatively, are reflective of the many diabetic patients who have 
relatively low plasma cholesterol, but still develop cardiovascular disease.  Thus, these mice may 
provide researchers with a model of diabetic atherosclerosis in which we can begin to separate and 
objectively examine many of the lipid-independent effects of diabetes on cardiovascular health.  
Further research employing this model of diabetic atherosclerosis will greatly aid in the dissection 
of cholesterol-independent mechanisms by which diabetes confers its atherogenic effects. 
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MACROVASCUALAR COMPLICATIONS OF DIABETES  
IN ATHEROSCLEROSIS-PRONE MICE80 
 
 
 
 
 
 
 
 
 
(This chapter consists of material from a manuscript reprinted with permission from Expert 
Reviews in Endocrinology and Metabolism; 2010 5(1), 89-98 (2010); titled “Macrovascular 
complications of diabetes in atherosclerosis-prone mice” by Lance A Johnson and Nobuyo 
Maeda) 
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4.1 Summary 
         The well-established relationship between diabetes and cardiovascular complications, 
combined with the rapidly increasing prevalence of diabetes, has created a pressing need for better 
understanding of the mechanisms of diabetic atherosclerosis.  Multiple metabolic and diabetes-
specific factors have been associated with accelerated atherosclerosis, including dyslipidemia, 
oxidative stress, inflammation, vascular cell dysfunction, and coagulopathy. This discussion 
highlights selected studies in which researchers have employed mouse models of diabetic 
atherosclerosis in an attempt to examine these mechanisms and to test potential therapeutic and 
preventative measures.   
 
 
 
 
 
4.2 Introduction 
            Each year, cardiovascular disease kills more Americans than any other cause of death (1).  
Diseases of the heart alone caused 30% of all deaths, with other diseases of the cardiovascular 
system causing substantially more death and disability (1).  Increasing this severe health burden is 
the rapidly increasing prevalence of diabetes.  The damage done by diabetes extends far beyond the 
typical microvascular complications of the disease, such as retinopathy and neuropathy.  Diabetics 
are 2 to 8 times more likely to develop CVD than non-diabetic patients, with up to 80% of patients 
with type 2 diabetes developing macrovascular disease (2-8).   Cardiovascular disease caused by 
atherosclerosis is the most significant complication of diabetes, as it is the leading cause of 
mortality among diabetic patients (6).   
            Several complex and interdependent metabolic conditions affect the pathogenesis of 
atherosclerosis in diabetes, including hyperglycemia, hyperinsulinemia and dyslipidemia.  These 
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metabolic disturbances are associated with increases in oxidative stress and glycation, endothelial 
dysfunction, inflammation, and a prothrombotic state that can influence all stages of atherogenesis 
(1, 8).  Despite the extensive clinical data linking diabetes and cardiovascular disease, many 
questions remain concerning the exact molecular mechanisms by which hyperglycemia and 
defective insulin signaling actions lead to macrovascular dysfunction.   
            Animal models have been invaluable in dissecting the various factors involved in the 
pathogenesis of diabetic macrovascular disease.  In recent years, more attention has been focused 
on mouse models to examine the factors that modulate diabetic atherosclerosis (9-10).  The mouse 
model is cost effective because of the small size of the animals and short generation time, and 
allows for well-controlled manipulations of diet, drugs, and other treatments. Above all, the mouse 
is currently the only species in which specific genetic mutations can be introduced into the genome 
with relative ease. Admittedly, mouse models are not able to completely mimic human diseases.  
Nevertheless, development of human-like atherosclerotic plaques in the aorta of hyperlipidemic 
mice, such as apolipoprotein E deficient (apoE-/-) mice and the low-density lipoprotein receptor 
deficient (Ldlr-/-) mice, has facilitated the investigation of macrovascular complications of 
diabetes using these models.  In this discussion, we review some of the recent studies of diabetic 
cardiovascular disease by highlighting the contributions of various atherosclerosis prone mouse 
models of diabetes.    
 
4.3 STZ- Induced Diabetes and Exacerbation of Atherosclerosis  
            Despite representing less than 10% of human diabetics, mouse models of type1 diabetes are 
used more often, in part due to their simplicity and ease of diabetes induction.  Chemicals such as 
alloxan and streptozotocin (STZ) have long been used to induce diabetes in rodents (11).  STZ is 
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an alkylating agent that causes DNA damage.  Since cellular uptake of STZ is mediated through 
glucose transporter 2 (Glut2), STZ is particularly toxic to the β-cells of the pancreas where Glut 2 
is highly expressed (12, 13).  A repeated administration of STZ at a low dose renders mice 
hyperglycemic with minimal toxic effects to other cells.  Although only males develop significant 
diabetes, thus limiting the scope of most studies, STZ treatment is rapid and effective.   
             Multiple studies have used STZ to induce diabetes in atherosclerosis-prone mice and 
confirmed that diabetes enhances atherosclerotic plaque development (Figure 4.1). The extent of 
enhancement as measured by the size of plaques in the cross section of aortic sinus, and/or by the 
plaque areas covering the aortic trees (en face), differ from experiment to experiment.  In general, 
plaque sizes in diabetic ApoE-/- mice average from 1.5 - 2 fold larger at the aortic sinus and 4 fold 
larger in aortic surface area compared to those seen in non-diabetic animals (Figure 4.1A).  The 
degree of atherosclerotic enhancement appears to strongly relate to the age of the animal at the 
time of onset, the duration of diabetes, and the type of diet on which the diabetic mice are 
maintained.  Thus, larger plaque enhancements are generally seen when apoE-/- mice are treated 
with STZ at younger ages when compared to the more modest effects of diabetes on the 
development of pre-existing plaques found in older mice.  Similarly, plaque-covered areas in the 
entire aorta appear to increase more during diabetes relative to the plaques in the aortic sinus alone, 
where plaques begins to develop at earlier age than other parts of aortic tree.  These phenomena 
suggest that diabetes accelerates initiation and growth during the early stages of plaque 
development, possibly through pathways of the inflammatory response.  Also important to note is 
that although lesions in diabetic animals are consistently larger than non-diabetic controls and 
therefore more advanced, plaques in diabetic mice are histologically no more complex than those 
of similar size seen in non-diabetic mice.  
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            Two to three fold increases in atherosclerosis have also been observed in LDLR-/- mice 
made diabetic by STZ treatment (Figure 4.1B).  In some studies, however, no increase in 
atherosclerosis was observed (14,16).  For example, Reaven et al reported that atherosclerosis in 
the LDLR-/- mice made diabetic with a single high dose of STZ and maintained on high fat diet for 
6 months did not differ from those in the control, non-diabetic, LDLR-/- mice (14).  The reason for 
this is not clear, but the plasma glucose levels in these diabetic mice were not as high as in other 
experiments because they were maintained on a low dose insulin infusion.  In addition, the plasma 
cholesterol levels were not significantly different between diabetic and non-diabetic mice.   
            In general, STZ-induced diabetes enhances plaque development in atherosclerosis prone 
mouse models, providing a suitable model system to evaluate perturbation or acceleration of the 
disease process through the manipulation of relevant factors. 
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Figure 4.1.  Effect of STZ-induced diabetes on atherosclerotic plaque size.  Change in 
atherosclerotic plaque area in STZ treated (A) ApoE-/- and in (B) LDLR-/- mice compared to non-
diabetic controls (selected studies). The duration of diabetes prior to atherosclerosis evaluation is 
represented by the horizontal length of the black bar.  Age at onset of diabetes is marked by the 
vertical portion of the black bar.        
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4.4 Genetic Models of Type1 Diabetes and Atherosclerosis 
            Genetic models of type1 diabetes are also available. Akita (Ins2C97Y/+) mice develop type 1 
diabetes due to a cysteine to tyrosine substitution at the amino acid position 97 in the insulin 2 gene 
(Ins2).  This mutation results in misfolding of preproinsulin, and triggers subsequent ER stress, β-
cell apoptosis, and insulin deficiency (17).   Similar to chemically induced models, diabetic 
phenotypes of Akita mice are also more severe in males than in females (18).  Studies of 
atherosclerosis prone mice in Akita background have yet to be reported. 
            The major cause of type1 diabetes in humans is not a direct loss of β cells as occurs in the 
mouse models discussed above, but instead appears to involve autoimmune responses and 
inflammatory processes which are triggered by injury and/or infection (19, 20).  Non-obese-
diabetic (NOD) mice spontaneously develop diabetes beginning at around five weeks of age due to 
lymphocytic infiltration of the pancreatic islets.  Similar to humans, their diabetes involves 
autoimmunity to islet cells as well as insulitis, but the genetics behind diabetes in NOD mice 
appears to be complex.  NOD mice are highly resistant to diet induced atherosclerosis development 
and neither diabetic nor non-diabetic NOD mice developed fatty streaks in their aortas when fed 
high fat, high cholesterol diets (21).  Introduction of proatherogenic mutations onto NOD 
background would be a worthwhile task.  
            An attractive diabetic model also involving autoimmune response was recently developed 
by Renard et al who created transgenic mice expressing the lymphocytic choriomeningitis virus 
glycoprotein (LCMV-GP) under control of the rat insulin promoter.  The GP mice express viral 
glycoprotein specifically in pancreatic β-cells and, after infection with LCMV, an immune 
response specifically destroys the β-cells, resulting in rapid development of type1 diabetes (22).  
When this GP transgene is placed onto LDLR-/- background, diabetic female mice developed 2.2 
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and 2.5 fold larger plaques compared to non-diabetic mice when they were fed 0.12% and 0.5% 
cholesterol diets, respectively (23).  Most strikingly, when mice with lesions of the same cross 
sectional area were compared, 60% of the plaques in diabetic mice fed high cholesterol diet 
(1.25%) compared to 12% of those in non-diabetic mice contained intralesional hemorrhage.  
Thus, diabetes in combination with a high cholesterol diet severely decreased plaque stability in 
GP-LDLR-/- mice. 
            These genetic models of type 1 diabetes are often not as simple as chemically induced 
diabetic models.  However, they do avoid the potential toxicity caused by chemical treatments, 
which can alter the pathogenesis of diabetic complications.  Together, both chemical and genetic 
models of type1 diabetes provide researchers with several unique and viable options for the 
induction of an insulin deficient state. 
 
4.5 Atherosclerosis in Models of Type2 Diabetes 
            An alarming health issue in recent years is the increase of metabolic syndrome, a cluster of 
metabolic-related abnormalities that predispose individuals to development of type 2 diabetes (24, 
25).  The characteristics present in metabolic syndrome include insulin resistance, hypertension, 
obesity and dyslipidemia: traditional risk factors for atherosclerosis (24).   The etiology of both the 
metabolic syndrome and type 2 diabetes are highly complex.  Thus, many studies employing 
models of type 2 diabetes have focused on investigating the pathophysiological links between 
specific aspects of the disease and atherosclerosis.   
            LDLR and ApoE deficient mice have been combined with leptin-deficient (ob/ob) and 
leptin receptor-deficient (db/db) mice to produce obesity-induced diabetic models of 
atherosclerosis (26-29).   Both backgrounds markedly increase plasma cholesterol and triglyceride 
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levels when compared to non-diabetic littermates.  However, accelerated atherosclerosis is 
observed in some, but not all, experiments (26, 27).   The reasons for these discrepancies are not 
clear but may be due to the differences in conditions such as diets used in each experiment.   
Because atherosclerosis-prone mice such as ApoE-/- and LDLR-/- mice have disturbed lipoprotein 
metabolism, dietary fat intake has profound effects on their overall energy metabolism.  Therefore, 
it is important to consider fundamental differences in these two models in terms of metabolic 
consequences.  For example, careful observations by Schreyer et al have shown that apoE-/- and 
LDLR-/- mice respond differently to diets high in fat and sucrose (30).  LDLR-/- mice exhibited 
increased susceptibility to diet-induced obesity, hypertriglyceridemia, leptin resistance, and 
impaired glucose metabolism.  In contrast, apoE-/- mice were resistant to diet-induced 
hypertriglideridemia or hyperglycemia despite of significant weight gain (30).   The absence of 
apoE in mice is also reported to reduce some of the metabolic complications associated with 
obesity (31).    
            Impaired insulin signaling also affects atherosclerosis in mice, and several studies have 
used partial or complete deficiencies in insulin receptors to re-create the effects of insulin 
resistance.  For example, apoE-/- mice completely lacking insulin receptor substrate protein 2 
(IRS2) are hyperinsulinemic and develop significantly increased atherosclerosis despite having 
comparable glucose and cholesterol levels to apoE-/- mice with wild type IRS2 (32).  Notably, a 
partial loss of IRS2 (IRS2+/-) also results in an acceleration of atherosclerosis in apoE-/- mice, 
despite indistinguishable levels of plasma lipids compared to control apoE-/- mice with full 
expression of IRS2 (33).  The authors suggest increased macrophage stimulation as a possible 
explanation for the plasma lipid-independent acceleration of atherosclerosis due to disrupted IRS2 
signaling.  Similarly, Biddinger et al showed that liver-specific ablation of insulin receptor (IR) 
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made mice susceptible to diet-induced plaque development (34).  However, Ldlr-/- mice lacking 
insulin receptor in peripheral tissues, but expressing low levels (less than 10 %) in the liver, had 
improved plasma lipid profiles and reduced atherosclerosis (35).     This study stresses the 
importance of hepatic insulin resistance on the regulation of lipoprotein metabolism and 
subsequently on the development of atherosclerosis (35).  Effects on atherosclerosis due to specific 
insulin defects in macrophages are controversial.  Han et al. showed that high fat fed Ldlr-/- mice 
transplanted with insulin receptor deficient bone marrow developed larger, more complex 
atherosclerotic plaques than those mice receiving wild type bone marrow (36).  In contrast, 
myeloid lineage cell-restricted ablation of IRS2 protected apoE-/- mice against atherosclerosis 
(37).   These different outcomes may be explained in part by the varied metabolisms of the two 
models, and in part by the intricate and multifaceted actions of insulin signaling.   
            Comparisons of the above studies highlight the metabolic differences often noted between 
insulin-deficient models of type 1 diabetes versus obesity-induced or insulin-signaling deficient 
models of type 2 diabetes.  Due to the complexity of most models of type 2 diabetes, caution is 
necessary when interpreting experimental outcomes.  However, when taken together, the studies 
employing various mouse models of type 2 diabetes demonstrate that both obesity and insulin 
resistance result in adverse metabolic conditions that increase atherogenesis in hyperlipidemic 
animals. 
 
4.6 Diabetic Dyslipidemia and Atherosclerosis 
            Type 2 diabetes, as well as poorly managed type1 diabetes, often leads to a cluster of 
harmful modifications to lipoproteins known as diabetic dyslipidemia (38, 39). Specifically, 
diabetic patients have elevated very low density lipoprotein (VLDL) triglycerides, a reduction of 
  108 
high density lipoprotein (HDL) cholesterol, and smaller denser LDL particles (40).   Since this 
lipoprotein profile is a risk factor for atherosclerosis, it has long been debated whether the 
enhanced atherosclerosis in diabetic mice may largely be a consequence of diabetes-induced 
hyperlipidemia (41, 42).  
            In our own experiment, we monitored the plasma lipid levels of diabetic apoE-/- mice fed a 
diet high in fat but low in cholesterol for 5 months after STZ treatment (43). ApoE-/- mice have a 
large accumulation of cholesterol-rich VLDL particles in plasma. We found that STZ-induced 
hyperglycemia did not significantly alter the plasma cholesterol and triglyceride levels of the mice 
during the first four months following the onset of diabetes. However, plasma cholesterol levels in 
some of the animals began to rise after four months, and these animals became severely 
hyperlipidemic.  Plasma cholesterol levels in these animals are correlated with the extent of liver 
damage characteristic of diabetes-associated steatohepatitis.  More importantly, the atherosclerotic 
lesion size in the individual diabetic apoE-/- mice, when evaluated at five months after the onset of 
diabetes, was not correlated with total plasma cholesterol or glucose levels (43). 
            Differing from the apoE-/- mice, LDLR-/- mice accumulate LDL-sized particles rather than 
VLDL particles in the plasma.  The plasma total cholesterol levels in the chow-fed LDLR-/- mice 
are about 200mg/dl, approximately half of those in apoE-/- mice, and they develop atherosclerosis 
much slower than apoE-/- mice.  Consequently, researchers   have fed diets containing high fat and 
modestly increased in cholesterol to LDLR-/- mice in order to accelerate the plaque development.  
(For example, a diet containing 21% fat and 0.15% cholesterol compared to 4.5% fat and 0.022% 
cholesterol in normal mouse chow). With this type of diet, Goldberg et al. showed that plasma 
cholesterol levels in the LDLR-/- mice doubled compared to non-diabetic controls immediately 
after they were treated with STZ (44).  The livers of diabetic LDLR-/- animals demonstrated a 
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reduced capacity to clear LDL and VLDL particles compared to the livers of non-diabetic animals, 
demonstrating the impairment of non-LDL receptor mediated clearance of apoB-containing 
lipoproteins during diabetes.  The authors suggest that the accumulation of a subclass of 
lipoproteins during diabetes, a group that is normally cleared efficiently, may explain the marked 
elevation of plasma cholesterol noted in STZ-induced diabetic LDLR-/- mice (44). 
The differential effects of hyperglycemia and hyperlipidemia on atherosclerosis were examined by 
Renard et al., in type1 diabetic GP, LDLR-/- mice (23).  They observed that when mice were on 
regular chow diet, although plasma cholesterol levels remained similar to non-diabetic mice, 
diabetes accelerated arterial macrophage accumulation and the initiation of atherosclerosis.  When 
fed diets containing increased amounts of cholesterol (0.12 and 0.5% cholesterol), however, mice 
with similar plasma cholesterol levels, whether diabetic or not, developed similar degrees of 
atherosclerosis (23).  The authors suggest that the development of large, advanced atherosclerotic 
lesions was dependent on dyslipidemia, which diabetic mice were far more susceptible to develop 
than non-diabetic mice.  Similarly, Reaven et al showed that STZ-induced diabetic LDLR-/- mice 
maintained with low dose insulin had similar plasma cholesterol levels with non-diabetic mice and 
had similar lesion sizes.  These mice were fed a high fat / high cholesterol diet, and all had severe 
hyperlipidemia (14).   Unlike in the type 1 diabetic  models described above, lesion size in a model 
of type 2 diabetic atherosclerosis (ob/ob;LDLR-/-) did not correlate with plasma total cholesterol 
or triglyceride levels (29).   
            Mouse models of type 2 diabetes generally develop increased plasma triglycerides and non-
esterified fatty acids (NEFA) as discussed above. In addition to its glucose regulatory effects, 
insulin normally acts to suppress hepatic VLDL secretion from the liver.  Hepatic insulin resistance 
is sufficient to cause dyslipidemia and enhanced atherogenesis through increased and/or 
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unregulated VLDL secretion, as well as decreased clearance of apoB-containing lipoproteins (34, 
35).  Thus, mice lacking insulin receptor (IR) in the liver show reduced HDL and increased VLDL 
and LDL (without affecting plasma total cholesterol), but reduced triglycerides, as a consequence 
of  an increased Pgc1β expression and decreased expression of Ldlr, Srebp1c and Srbp2 genes 
(34).   After 3 months on an atherogenic diet (15% fat, 1.25% cholesterol and 0.5% sodium 
cholate) the mice with hepatic insulin resistance raised their plasma total cholesterol levels to about 
750mg/dl, and induced substantial plaques in their aorta.   As described earlier, Han et al. observed 
that Ldlr-/- mice expressing low levels of insulin receptor  in the liver, but lacking it in peripheral 
tissues, had reduced VLDL and LDL levels, and reduced atherosclerosis.  The authors suggest that 
a 50% reduction in VLDL and LDL is sufficient to limit atherogenesis, overcoming the pro-
atherogenic effects of peripheral insulin resistance in vascular cells (35).   
            The research highlighted above demonstrates that hyperlipidemia is an essential component 
of diabetes-induced atherosclerosis.  However, exaggerated hyperlipidemia following the induction 
of diabetes may mask effects specific to hyperglycemia and/or insulin resistance, as well as 
overwhelm potential therapeutics or preventative measures.  Thus, researchers must be cautious 
when choosing the specific type of diet to be administered to diabetic mice in any given 
experiment.   While it is clear that diabetes-induced hyperlipidemia is a principal contributor to the 
development of cardiovascular disease, it is not the only contributor.  There are also many 
significant lipid-independent effects on diabetes-induced plaque development, as discussed below.   
 
4.7 Antioxidant Defense in Diabetic Atherosclerosis  
            Diabetes is usually accompanied by increased production of reactive oxygen species 
(ROS), free radicals and/or by impaired antioxidant defenses.  Thus, increased oxidative stress is 
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widely accepted as an important player in the development and progression of diabetes and its 
complications (45).  A decrease in intracellular antioxidants such as nitric oxide (NO) and various 
antioxidant enzymes may also affect direct trapping of free radicals, with a consequent increase in 
ROS and oxidative stress. Strong evidence also exists that oxidation of lipids, in particular LDL, is 
one of the most important factors for the initiation of atherosclerosis (46).  Furthermore, systemic 
oxidative stress can lead to acute phase responses including hypercoagulability and plaque rupture.  
These considerations have provided the rationale for the use of antioxidants to prevent lipid 
peroxidation and the early onset of atherosclerosis, and as therapies for coronary artery disease 
(47).  However, evidence linking antioxidant vitamins to diabetic complications in humans is still 
largely circumstantial.  For example, although treatment with a high-dose of vitamin E (1800 IU / 
day) appeared to be effective in normalizing retinal hemodynamic abnormalities and improving 
renal function in type 1 diabetes in a small randomized trial (48), vitamin C at a dose of 400IU/day 
had no effect on cardiovascular outcomes or nephropathy in high-risk patients with diabetes in the 
HOPE study and MICRO-HOPE sub-study (49). 
            Dietary supplementation of vitamin E, a natural anti-oxidant, decreased the amount of 
macrophages and vascular fatty streaks, as well as lowered the mortality rate, in STZ-induced 
diabetic Balb/c mice fed an atherogenic diet (50).  However, Balb/c mice are resistant to diet-
induced atherosclerosis (51), and protective effects of vitamin on diabetes-induced fully developed 
have not been examined.  However, Hasty et al. showed that this protective effect was absent when 
observing the obese, hyperlipidemic LDLR-/-;ob/ob mouse model, as dietary supplementation of 
Vitamin E failed to reduce oxidative stress or atherosclerotic lesion area (26).   
            Reduced plasma vitamin C levels have been associated with diabetes in humans (52-54).  
However, mice, unlike humans, synthesize ascorbic acid and hence are not dependent on dietary 
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vitamin C.  To examine the effects of sub-optimal vitamin C intake, our lab created apoE-/- mice 
that are deficient of L-glonolactone synthase, the key enzyme for ascorbic acid synthesis, and 
tested the effect of reduced plasma vitamin C (ascorbic acid) levels on plaque development (55).  
Mice were made diabetic and maintained on low (66mg/l) or high (660mg/l) levels of ascorbic acid 
supplemented in their drinking water.  We found that vitamin C levels in both plasma and liver of 
mice supplemented with low vitamin C were less than 20% of those in diabetic mice given high 
vitamin C supplementation (as well wild type mice).  However, the atherosclerotic plaque size did 
not differ between the two groups.  Thus, it appears that the level of Vitamin C reduction does not 
have any effects on diabetes-induced atherosclerosis.    
            In contrast, a dietary supplementation of α-lipoic acid (LA), another natural antioxidant, 
completely prevented the diabetes-associated increase of the atherosclerotic lesion size in 
diabetic apoE-/- mice fed a high fat – low cholesterol diet (43).  LA markedly decreased 
systemic oxidative stress, suggesting that a protection of lipoprotein from oxidative modification 
by LA probably is an important factor for reduced atherosclerotic lesion development.  However, 
LA treated diabetic mice also had lesser diabetes-induced body weight reduction, milder 
dehydration, protection from hepatitis, and an accelerated recovery of pancreatic β-cells which 
lead to a small, but significant, reduction of hyperglycemia over time compared to non-treated 
diabetic mice. Thus, an improvement in general health likely contributes to the protection from 
atherosclerosis enhancement in LA-treated diabetic mice.  Of note, we as well as others, 
observed that dietary α-lipoic acid also decreases atherosclerotic lesions in non-diabetic apoE 
mice without affecting their plasma cholesterol levels (56).  The reduction (10-20%) is small, but 
suggests that α-lipoic acid may have additional athero-protective roles beyond the reduction of 
hyperglycemia-induced ROS. 
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            The role played by genetically determined differences in the endogenous antioxidant 
enzymes in affecting oxidative stress and the development of complications in diabetes was also 
addressed by de Haan and his colleagues.  The authors showed that a deficiency of glutathione 
peroxidase-1 (GPx-1) caused a 2 fold increase in aortic lesions in diabetic apoE-/- mice (57).  This 
atherosclerotic effect occurred despite the fact that lack of Gpx-1 did not affect plasma lipid 
profiles. The study demonstrates that an intracellular ROS-removing antioxidant enzyme GPx1 
plays important roles in regulating atherogenic processes within a diabetic milieu.  Recently, the 
group also showed that oral administration of ebselen, a GPx1-mimetic and antioxidant, 
significantly reduced aortic lesions in diabetic apoE-/- mice (58).  The reduction was site-specific, 
and the plaque size in the aortic root was not changed.  Experiments using cultured endothelial 
cells suggest that one of the key mechanisms whereby ebselen confers its antiatherogenic effect is 
through modulation of inflammatory factors by inhibiting the activation of nuclear factor kappa B 
(NF-κB).    
            Aldose reductase (AR) catalyzes the reduction of glucose to sorbitol, one of several 
pathways thought to accelerate diabetic complications via production of excess ROS.  This enzyme 
is expressed at much lower levels in mice compared to humans. To test the hypothesis that greater 
expression of a gene involved in the toxic metabolism of glucose would enhance diabetic induced 
atherosclerosis, Vikramadithyan et al made diabetic LDLR-/- mice that over-express human AR 
(hAR) (59).  They found that the over-expression of AR increased aortic lesion size in diabetic 
LDLR-/- mice without affecting the plasma cholesterol levels.  Accumulation of modified 
lipoproteins was increased in macrophages of the hAR-expressing mice, and expression of 
enzymes that regulate regeneration of glutathione was reduced in the aortas.  The authors have 
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suggested that the inhibitors of AR could, therefore, be useful in the treatment of diabetic 
atherosclerosis. 
            These studies demonstrate that reducing the excess ROS production caused by diabetes has 
a significant protective effect on the progression of atherosclerosis.  However, effects of individual 
antioxidants vary greatly, and suggest that targeting specific cellular oxidative pathways may be 
more effective than a global supplement-based reduction in oxidative stress. 
 
4.8 Other Modulations of Diabetic Atherosclerosis 
            Important by-products of hyperglycemia are advanced glycation end products (AGEs), 
which result from the nonezymatic glycation of circulating proteins.  Binding of AGEs to their 
receptor (RAGE) induces several inflammatory markers and accelerates vascular lesion 
development (60).   Park et al. showed the therapeutic potential of soluble RAGE (sRAGE) to 
inhibit the activation of RAGE pathway in diabetic apoE-/- mice, where sRAGE administration 
completely prevented diabetes-associated increase in atherosclerosis independent of both plasma 
glucose and lipids (61).  In addition to preventing the early stage acceleration of atherosclerosis as 
a result of diabetes, RAGE suppression also worked to stabilize existing plaques by lowering 
inflammatory markers and decreasing macrophage and smooth muscle cell (SMC) activation in 
existing atherosclerotic lesions (62).   These reductions in diabetes-associated atherosclerosis 
highlight the beneficial effects of attenuating AGE and RAGE accumulation, and subsequent 
inflammatory response, in the atherosclerotic plaque development. 
            In addition to its vasoconstrictive effects, enhanced activity of the renin-angiontensin 
system (RAS) may be a detrimental link between several atherosclerotic risk factors, contributing 
to an increased production of ROS, insulin resistance, and further endothelial dysfunction.  
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Blockade of the RAS by angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor 
blockers (ARBs) has been tested in mouse models of diabetic atherosclerosis.  For example, 
Candido et al. showed that the induction of diabetes triggers an increase in the expression of 
angiotensin-converting enzyme (ACE) in the aorta of STZ treated apoE-/- mice. The treatment 
with an ACE inhibitor, perindopril, inhibited this diabetes-induced increase of aortic ACE 
expression and completely inhibited atherosclerotic lesion development, despite only modestly 
decreasing systolic blood pressure (SBP) (7-8 mm Hg) (63).    A similar result was noted when 
diabetic mice were treated with the angiotensin II type 1 (AT1) receptor blocker, Irbesartan, which 
decreased collagen content, cellular proliferation, macrophage infiltration, lowered expression of 
several markers of inflammation, and attenuated atherosclerotic plaque development.  Despite 
lowering the SBP of diabetic mice to a similar degree as Irbestan (7 and 8 mm Hg, respectively), a 
calcium channel blocker, amlopidine, did not halt the acceleration of atherosclerosis as did 
Irbesartan (64).  Thus, the attenuation of atherosclerosis was specific to the inhibiton of AT1 and 
not solely a result of lowering SBP. 
            Finally, links between hyperglycemia, inflammation, and vascular thrombotic 
complications in diabetic atherosclerosis have been examined.  Zuccollo et al demonstrated the 
atherosclerosis inhibiting effects of S18886, a thromboxane A2 receptor (TP) antagonist.  S18886 
significantly protected from diabetic lesion progression in STZ-treated apoE-/- mice.  It also 
prevented the decrease in endothelial nitric oxide synthase (eNOS) expression and the increases in 
several markers of inflammation that normally occur after the induction of diabetes (65).   In 
addition, the role of platelet-derived growth factor in the development of diabetes-induced 
atherosclerosis was examined by Lassila et al.  They showed that tyrosine kinase inhibition by 
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imatinib lowered the expression of inflammatory cytokines in the aorta and slowed the progression 
of atherosclerosis in diabetic ApoE-/- mice. 
            Jointly, these experiments suggest that modulation of vascular function in diabetic animals 
has generally beneficial effects, and is protective from the acceleration of diabetes-induced 
atherosclerosis. 
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Figure 4.2.  Commonly used mouse models of diabetic atherosclerosis.  Each circle represents a 
distinct mouse model of Atherosclerosis (Blue), Type 1 Diabetes (Red), or Type 2 diabetes 
(Orange). Size of each circle is a general reference to the number of studies employing each model. 
Areas of overlap represent combinations/crosses of these various models (selected studies) and 
include reference number.  Apolipoprotein E (ApoE), Apolipoprotein B (ApoB), Balb/c (B/c), 
Insulin Receptor (IR), Insulin Receptor Substrate 2 (IRS2), Low density lipoprotein receptor 
(LDLR), streptozotocin (STZ). 
  
  118 
4.9 Expert Commentary 
            The global epidemic of obesity and metabolic syndrome means millions of additional 
patients will soon find themselves with a severely increased risk of developing cardiovascular 
disease (66).   This rapidly expanding health burden has created a pressing need for further 
exploration of the biological mechanisms of diabetic atherosclerosis, and has placed a tremendous 
value on the discovery of new therapies.  Because the pathophysiology of metabolic syndrome and 
type 2 diabetes is far more complex than that of type 1 diabetes, there are limitations in the use of 
atherosclerosis prone mouse models to dissect the underlying mechanisms of how the diabetic 
condition enhances cardiovascular complications.  
            To study the pathogenesis of diabetic atherosclerosis, and to correctly translate the findings 
to human disease, further development of models that accurately recapitulate the human diabetic 
condition are needed.  They include models of type 2 diabetes that account for important 
differences in human versus mouse physiology, as well as models that demonstrate reduced plaque 
stability, increased thrombosis, and common human vascular events such as myocardial infarction 
and stroke. 
            In this regard, the ApoE triple knockout (ApoE-/-;ApoB100/100; ob/ob) and the LDLR 
triple knockout (LDLR-/-;ApoB100/100;ob/ob) models of metabolic syndrome are worth 
mentioning since both strains, on normal mouse chow, develop obesity, hyperinsulinemia, 
hyperlipidemia, hypertension, and accelerated atherosclerosis - the components of the metabolic 
syndrome (67).  The Apob100/100 homozygous mutation in these mice results in a plasma 
accumulation of atherogenic lipoprotein particles containing apolipoprotein B-100, which is more 
similar to human lipoprotein profiles.  Despite the complexity of these models, both recapitulate 
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the cluster of disorders central to the metabolic syndrome, and might prove to be useful tools in the 
search for potential therapies for this uniquely human condition. 
            One of the inherent limitations of the commonly used models of atherosclerosis is that both 
the apoE and Ldlr proteins, integral components in the pathophysiologic process of atherosclerosis, 
are lacking.  Models in which these proteins, and other essential factors, are present but functioning 
sub-optimally may provide more accurate insights and better translate to the human condition.  For 
example, our laboratory has begun to explore the progression of atherosclerosis in mice that carry 
two copies of the human apolipoprotein E isoforms as well as express human Ldlr (68).  These 
mice develop significant atherosclerotic plaques and demonstrate diabetes-induced increases in 
aortic lesions when made diabetic by acquiring the Akita mutation.  Most importantly, these mice 
retain all the critical proteins - mainly apoE, LDLR, and insulin receptor - involved in lipoprotein 
metabolism, in contrast to other athero-prone models that lack one or more of these components. 
 
4.10 Five Year View 
            Further studies focusing on diabetic atherosclerosis will not only help to determine the 
underlying factors that are important in the pathogenesis of cardiovascular disease in the setting of 
diabetes, but may also reveal therapeutic avenues and preventative measures.  Creative use of 
existing mouse models and the generation of new models, particularly those that sufficiently 
address the human condition, will provide an invaluable platform to examine the specific 
mechanisms by which diabetes exerts its effect on the vasculature and to test the potential of new 
therapies and treatments. 
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Table 4.1 Key Issues. Macrovascular complications of diabetes. 
 
Key Issues 
 
• Diabetes accelerates atherosclerosis and its cardiovascular complications.  Atherosclerosis 
prone mice (ApoE-/- and LDLR-/-) have been used extensively to examine the mechanisms 
by which hyperglycemia and/or defective insulin actions advance macrovascular disease. 
 
• The most commonly used mouse models of diabetic atherosclerosis are STZ-treated ApoE-
/- and LDLR-/- mice.   
 
• Diabetes generally increases atherosclerotic plaque size in athero-prone mice.  The 
atherosclerosis model employed, age of onset and duration of diabetes, as well as diet, 
affect lesion progression. 
 
• Diabetes induces hyperlipidemia, which is exaggerated by high fat/cholesterol diets,  is 
required for the development of advanced atherosclerotic plaques in mice. Other important 
lipid-independent atherogenic effects could be masked by this severe dyslipidemia.  
 
• Lipid-independent effects of diabetes demonstrated in mouse models of diabetic 
atherosclerosis include oxidative stress, glucose toxicity, inflammation, endothelial 
dysfunction, coagulopathy, and dysfunction of the renin-angiotensin system. 
 
• Targeted intervention of these processes in mice have produced promising approaches 
towards the amelioration and prevention of diabetic atherosclerosis. 
 
• More “human-like” mouse models are needed that accurately replicate human lipoprotein 
and glucose metabolism, as well as those that demonstrate the clinical complications of 
atherosclerosis (decreased plaque stability and rupture). 
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CONCLUSIONS AND SIGNIFICANCE 
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5.1 ApoE in Diabetic Dyslipidemia:  Hyperlipidemia 
 
        In Chapter 2, I described the differential roles of apolipoprotein E (apoE) isoforms in 
modulating diabetic dyslipidemia – a potential cause of the increased cardiovascular disease risk of 
patients with diabetes.  Using LDLR deficient mice crossed with the human apoE mouse models 
described earlier and employing a chemically induced model of type 1 diabetes, I observed several 
important phenomena.   
        First, non-diabetic E3LDLR-/- and E4LDLR-/- mice had similar plasma glucose and lipids, 
lipoprotein distribution profiles and indistinguishable degrees of atherosclerosis.   However, after 
the induction of diabetes, E4LDLR-/- mice, but not E3LDLR-/-, develop enhanced dyslipidemia, 
characterized by elevated VLDL TG and LDL cholesterol, delayed clearance of post-prandial 
triglycerides, and an increased rate of VLDL secretion (Figure 5.1).  The increase in plasma VLDL 
and LDL cholesterol was not a result of a difference between E3 and E4 lipoprotein composition, 
hepatic receptor expression, or VLDL/LDL clearance rates.  Instead, the primary difference noted 
between the E3 and E4 expressing mice was E4-specific increase in hepatic VLDL secretion. 
Using in vivo techniques as well as cultured primary E3 and E4 hepatocytes as an in vitro model 
system, I determined that the increase in VLDL secretion was a result of larger hepatic fat stores in 
the E4 mice.   
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Figure 5.1.  Severe dyslipidemia and atherosclerosis in diabetic E4LDLR-/- mice.  Induction of 
diabetes leads to an increase in hepatic VLDL secretion (red arrow) in E4LDLR-/- mice.  The  
increase in VLDL secretion leads to an accumulation of plasma VLDL (large red circles).  As 
circulating VLDL is lipolyzed it becomes the denser, cholesterol-rich LDL particles (small red 
circles).  LDL contributes to the development of the atherosclerosis. Thus, the diabetes-induced 
increase in LDL in the diabetic E4LDLR-/- mice leads to larger atherosclerotic plaques. 
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       The severe dyslipidemia in the diabetic E4LDLR-/- mice is associated with a calorimetric 
profile indicative of lower lipid utilization, suggesting that the accumulation of hepatic fat stores in 
these mice could be a result of a decrease in lipid burning.   When primary hepatocytes isolated 
from E4LDLR-/- mice were cultured in high glucose, they accumulated more intracellular lipid.  
This accumulation was not a result of a difference in fatty acid uptake, glucose uptake, de novo 
lipogenesis, or glucose oxidation between the E3 and E4 expressing hepatocytes.  However, there 
was a striking reduction in fatty acid oxidation in the E4 hepatocytes only when exposed to the 
hyperglycemic conditions (Figure 5.2).  The reduction in fatty acid oxidation in the E4 expressing 
livers was associated with a significant shift in oxidative signaling pathways.  Diabetic E4LDLR-/- 
mice had a reduced phospho-Acetyl CoA Carboxylase (pACC) to Acetyl CoA Carboxylase (ACC) 
ratio, which is indicative of increased lipogenesis and decreased fatty acid oxidation. E3LDLR-/- 
mice showed a diabetes-induced decrease in Fatty Acid Synthase (FASN) gene expression as 
expected.  However, diabetic E4LDLR-/- mice maintained high levels of FASN expression before 
and after the induction of diabetes.  Thus, lipid accumulates in the E4LDLR-/- livers during 
diabetes via two metabolic pathways:  high, unresponsive levels of fatty acid synthesis and a 
significant reduction in fatty acid oxidation. 
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Figure 5.2.  Mechanism of hepatic lipid accumulation in diabetic E4LDLR-/- mice. Reduced 
fatty acid oxidation in E4LDLR-/- hepatocytes contributes to the accumulation of hepatic lipid.  
Ldlr-/- hepatocytes expressing apoE4 accumulated twice as much lipid as those expressing E3 
when cultured in a high glucose environment.  Metabolic studies involving C14 labeled glucose and 
fatty acids demonstrated that this accumulation was not due to an increase in fatty acid uptake, 
glucose uptake and de novo lipogenesis, nor a decrease in glucose oxidation.  Instead, the E4 
hepatocytes accumulated lipid due to a 40% reduction in rates of fatty acid oxidation. 
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      In summary, I showed that dyslipidemia and atherosclerosis were greatly exaggerated in 
diabetic LDLR-/- mice expressing human apoE4 (E4LDLR-/-) compared to those with human 
apoE3 (E3LDLR-/-), despite a similar degree of hyperglycemia.  Diabetes increased VLDL 
triglycerides and LDL cholesterol in E4LDLR-/- mice twice as much as in E3LDLR-/- mice, and 
diabetic E4LDLR-/- mice had delayed clearance of post-prandial triglycerides, larger hepatic fat 
stores, and increased VLDL secretion.  Diabetic E4LDLR-/- mice demonstrated a decreased 
reliance on lipid as an energy source based on indirect calorimetry and had a hepatic metabolic 
profile indicative of reduced fatty acid oxidation and increased fatty acid synthesis.   
        Strikingly, the presence of the E4 allele resulted in severe dyslipidemia and atherosclerosis 
independent of its interaction with LDLR.  This E4-specific aggravation of diabetic dyslipidemia is 
central to the liver and appears to be the result of a novel role of apoE in the regulation of hepatic 
lipid metabolism.  That is, ApoE4 expressing livers had reduced fatty acid oxidation, which 
contributed to the accumulation of tissue and plasma lipids and subsequent atherosclerosis.   
  
  134 
5.2 ApoE in Diabetic Dyslipidemia: Normolipidemia      
 
        In Chapter 3, I investigated a similar issue as in Chapter 2, this time taking a very different 
approach.  Instead of using a hyperlipidemic mouse model like the LDLR-/-, I employed mice that 
overexpressed the human LDLR gene, resulting in a model with very low plasma cholesterol.  
Previous work in our laboratory has shown the importance of the apoE-LDLR interaction in terms 
of regulating lipoprotein metabolism and the development of atherosclerosis.  By crossing human 
apoE mice that overexpress the LDLR to strains carrying the type 1 diabetes ‘Akita’ mutation, I 
was able to examine the role of apoE in diabetic dyslipidemia in a more physiologically relevant 
setting.   
      Additional factors contribute to the increased CVD risk for patients with diabetes beyond the 
diabetic dyslipidemia described in earlier chapters.  These include factors such as inflammation, 
endothelial dysfunction, hypertension, and a pro-thrombotic state (1). However, due to the 
limitations of currently used disease models, past research has often failed to adequately separate 
the effects of these important factors from the overwhelming dyslipidemic response that occurs in 
response to diabetes in these models (2).  The main hurdles for researchers studying vascular 
pathologies during diabetes have been an inability to consistently demonstrate a diabetes-induced 
increase in atherosclerosis, and in the cases where they are able, difficulties distinguishing between 
lipid-dependent and lipid-independent effects of diabetes on atherosclerosis (2-3).  Moreover, the 
mouse models of atherosclerosis currently available all have plasma cholesterol levels that far 
exceed the physiological range in human patients.  Therefore, an important goal has long been the 
generation of a model of diabetic atherosclerosis in which the CVD inducing effects of diabetes are 
not obscured by severe hyperlipidemia. 
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     In Chapter 3, I introduced a new mouse model of atherosclerosis that clears these hurdles, 
allowing researchers for the first time to study the atherogenic etiology of diabetes in a metabolic 
setting that accurately reflects the human condition.  The diabetic E4h mouse develops 
spontaneous atherosclerotic plaques in spite of low total plasma cholesterol levels (<175 mg/dl).  
The main advantages of this new model are outlined in Table 5.1 and include:  1) consistent 
development of atherosclerotic plaques induced by diabetes, 2) no toxic side effects of chemical 
induction of diabetes, 3) all the components of lipoprotein metabolism are present (and 
“humanized”), 4) no additional high fat or high cholesterol diet is necessary to induce 
atherosclerosis, and 5) atherosclerosis occurs in the absence of hyperlipidemia (Table 5.1). 
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Athero 
Model 
Diabetes 
induced by: 
ApoE 
preent? 
LDLR 
present? 
Does diabetes 
increase athero? 
Cholesterol 
(mg/dl) 
Ref. 
ApoE-/- STZ no yes yes 500 - 1,300 # 20-22 
ApoE-/- leptin def. no yes yes 580 # 23 
Ldlr-/- STZ yes no no 950 - 1000 # 24 
Ldlr-/- leptin def. yes no yes 1,700 # 25 
E4h Akita yes, human yes, human yes < 125 unpub. 
 
 
Table 5.1.  Advantages and disadvantages of common models of diabetic atherosclerosis.  
Four of the most commonly used models of diabetic atherosclerosis and the E4h model are 
compared in regards to several important factors.   Abbreviations:  apolipoprotein E deficiency 
(apoE-/-), Ins2+/- Akita mutation (Akita), high fat diet (HFD), low density lipoprotein receptor 
deficiency (Ldlr-/-), leptin deficiency (db/db and ob/ob models) (leptin def.), streptozotocin (STZ), 
unpub (unpublished data). 
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      In addition to providing a new model of diabetic atherosclerosis, this study was able to address 
the importance of the apoE-LDLR interaction during diabetes.  While increasing LDLR expression 
in the presence of apoE3 during diabetes had no detrimental effects, doing so in the presence of 
apoE4 resulted in a significant increase in VLDL and decrease in HDL cholesterol – two harmful 
changes to lipoprotein metabolism that are commonly associated with diabetes in human patients.  
In essence, the effects of diabetes on dyslipidemia were amplified in mice expressing apoE4 
(Figure 5.4). 
      Diabetes had no effect on total plasma cholesterol in E3 and E3h mice, but induced a 20 and 
50% increase in the plasma cholesterol of E4 and E4h mice, respectively.  Still, average total 
plasma cholesterol in all the diabetic groups remained <120 mg/dl, compared to average total 
cholesterols ranging from 300-1700 mg/dl in other common models of diabetic atherosclerosis.  
The cause of atherogenesis in the diabetic E4h mice instead arose from the specific types of 
lipoproteins that accumulated in these mice and in particular the cholesterol distribution among 
them.  The accumulation of cholesterol-rich VLDL and VLDL remnant particles in the diabetic 
E4h appears to be a result of an increase in hepatic VLDL secretion.  Previous work has implicated 
both apoE and LDLR in the process of apoB lipidation and VLDL secretion (4).  However, the 
impact of overexpressing the LDLR on VLDL secretion during diabetes had not been examined.  
Interestingly, overexpressing the LDLR in E4 mice resulted in the secretion of primarily apoB48-
containing, triglyceride-poor, cholesterol-rich VLDL (Figure 5.5).   
        In summary, this study highlights the importance of adequately regulating VLDL secretion 
during diabetes and the significance of the quality (VLDL/LDL versus HDL, protein and lipid 
composition of various lipoprotein fractions and the distribution of cholesterol among the various 
fractions) versus solely quantity of lipoproteins.  
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Figure 5.3.  Summary of plasma lipids in non-diabetic and diabetic E3 and E4 models.  
Arrows moving from left to right indicate an increase in LDLR expression as a result of the h/+ 
genetic manipulation.  Arrows moving from top to bottom indicate the induction of diabetes as a 
result of the Ins2+/- “Akita” mutation.  Diabetes induces an increase in VLDL cholesterol in the 
presence of E3 and E4.  Likewise, an increase in LDLR reduces HDL cholesterol in both E3 and 
E4 expressing mice.  However, atherosclerosis occurs only in the presence of both severely 
elevated VLDL cholesterol and reduced HDL cholesterol, as is the case in the diabetic E4 h/+ 
mice. 
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Figure 5.4.  Proposed mechanism of cholesterol accumulation in diabetic E4h mice.  Diabetic 
E4h secrete more cholesterol-rich VLDL compared to diabetic E3h mice. Combined with their low 
HDL cholesterol levels, and thus likely impaired reverse cholesterol transport, the diabetic E4h 
mice develop atherosclerosis. 
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5.3 Tying it all together:  Diabetic Atherosclerosis and the Role of ApoE 
 
      In order to effectively study the process of diabetic atherosclerosis and more importantly in 
order to appropriately translate the implications to the human condition, models that consistently 
and accurately reflect diabetes and atherosclerosis in human patients are needed.  In order to 
address this issue while examining the role of apoE in diabetic dyslipidemia and atherosclerosis, I 
employed the ‘humanized’ E3LDLR-/- and E4LDLR-/- mice described in Chapter 2.  Using these 
models, I demonstrated a dramatic exacerbation of diabetes-induced hyperlipidemia in the 
presence of the E4 allele. 
        However, as described in Chapter 4, one of the major hurdles for researchers has been the 
confounding issue of diabetes-induced hyperlipidemia and the consequent difficulty in separating 
its effects on the progression of atherosclerosis from other lipid-independent factors.  Thus, while 
the LDLR deficient mice employed in the study described in Chapter 2 provided an important new 
look at the role of apoE in diabetic dyslipidemia, it is difficult to completely reconcile the data with 
the human condition due to the hyperlipidemia associated with the LDLR-/- model.  In Chapter 3, I 
introduced a new mouse model of diabetic atherosclerosis that consistently develops 
atherosclerosis despite low plasma cholesterol, thereby circumventing this difficult issue.  To our 
knowledge, this is the first mouse model of diabetic atherosclerosis with physiologically relevant 
plasma lipids (cholesterol <125 mg/dl), providing researchers with an important new tool to begin 
to discriminate between diabetes-induced hyperlipidemia and lipid-independent effects of diabetes.  
In addition, this new model may allow for studies of other complications of diabetes such as 
diabetic nephropathy or diabetic retinopathy.  Interestingly, I observed a diabetes-induced 
development of atherosclerosis in the presence of apoE4, but not apoE3. As noted above, this was 
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due to a distinct, apoE4-specific shift in the type and composition of lipoproteins circulating during 
diabetes.  Importantly, I demonstrated that the presence of apoE4 led to more severe diabetic 
dyslipidemia at both ends of the LDLR spectrum; LDLR deficiency in Chapter 2 and increased 
LDLR expression in Chapter 3.  Of interest in regards to the high end of the spectrum (increased 
LDLR expression; Chapter 3), are the potential implications for patients taking Statins, a popular 
cholesterol lowering class of drugs.  Interstingly, minimal and maximal effects of Statin therapy 
have been shown in E4 and E2 patients, respectively (5).  Previous work in our laboratory, in 
addition to the data I have presented in Chapter 3, show that overexpression of the LDLR is 
detrimental in the presence of apoE4.  However, in addition to reducing cholesterol synthesis, one 
of the beneficial effects of the statin class of drugs is to increase in LDLR expression.  Our work 
shows that in a mouse model, there are harmful effects of an increase in LDLR in the presence of 
E4, such as higher levels of apoE-poor VLDL, an increased rate of hepatic cholesterol secretion, 
and more atherosclerosis.  Whether these data translate directly to human patients and whether this 
stain-induced increase in LDLR expression is indeed beneficial in E4 carriers is an important 
question that requires further research.  Regardless of the answer to this question, when taken 
together, this work not only highlights the dramatic effects of even subtle changes in lipoprotein 
distributions during diabetes, but also underscores the essential role of apoE, and the importance of 
APOE genotype, on the pathogenesis of diabetic dyslipidemia and atherosclerosis.  
    As mentioned in the introduction, apoE isoform distributions vary widely with ethnicity.   E4 
carrier frequency ranges from as low as 5% in groups of European ancestry, such as in Sardinia, 
and reach as high as 41% in groups with direct hunter-gatherer origins, such as the Biaka people of 
central Africa (6).  The high frequency of E3 in populations with a long history of agriculture and 
the high frequency of the “ancestral” E4 allele in Native American and Aboriginal populations has 
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led people to suggest that APOE is a thrifty gene (6-7). One theory is that apoE4 helped extended 
LDL circulation time and kept cholesterol levels at healthy levels when meals were few and far 
between (6).  I believe that now, in a American culture of consistent meals and caloric excess, 
apoE4 instead leads to chronically elevated cholesterol levels and is thus a risk factor for CVD.  
Due to the sheer number of E4 carriers (~25% of the United States population), the predisposition 
to elevated cholesterol among these patients is a huge health burden.  Given the important interplay 
between glucose and lipid metabolism, the crucial epidemiological studies that demonstrate a clear 
association between APOE genotype and glucose metabolism (8-15), further complicate the 
burden.  
         The studies described here raise additional important questions about the role of insulin in 
regulating these apoE4-specific effects.  Are the effects described in these studies a result of insulin 
deficiency,insulin resistance and defects in insulin signaling, or hyperglycemia alone?  Previous 
studies in our lab also strongly suggest that apoE4 is associated with obesity and insulin resistance 
(16-17).  Therefore, future studies aimed at further dissecting the specific metabolic pathways by 
which apoE4 exerts its detrimental effects will be of great importance.  Some investigations are 
already underway in our laboratory.  For instance, I have co-authored two papers in which our 
laboratory demonstrated that apoE4 mice fed a Western type diet are more prone to become insulin 
resistant because they have a reduced ability to store fat in adipose tissue depots compared to 
apoE3 mice (16-17).  Reduced functionality of adipose tissue during a metabolic disturbance such 
as a high fat diet is rooted in an impaired activation of the adipogenic genetic program.  The 
insulin-sensitizing drugs known as Thiazolidodiones (TZDs) are a commonly prescribed treatment 
for type 2 diabetes.  However, we have shown that Rosiglitazone (or Avandia), a commonly 
prescribed TZD before it was pulled from the market due to cardiovascular risk, had unintended 
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and potentially harmful effects in mice with E4, but not in those with E3.  We showed that 
stimulation of PPAR gamma by rosiglitazone – the mode of action of TZDs – resulted in 
pathological accumulation of fat in the liver, instead of normal functional accumulation in adipose 
tissue, in mice with E4.  This raises another important question for E4+ patients:  Do other drugs in 
this class (TZDs) have a similar interaction with apoE?  Although the mechanism underlying these 
phenomena has yet to be fully determined, reduced insulin sensitivity in the presence of apoE4 
could have a significant impact on adipocyte function as well as lipid metabolism.  This is 
particularly of interest when considering hypoinsulinemic conditions such as the genetic (Akita) 
and chemical (STZ) models of type 1 diabetes employed in Chapters 2 and 3.   
       The work described here raises several important questions concerning the dyslipidemic and 
pro-atherosclerotic effects of apoE during diabetes.  For example, could apoE act as a metabolic 
signaling molecule?  The experiments involving the regulation of Acetyl-CoA Carboxylase (ACC) 
in the latter part of Chapter 2 suggest that this is a possiblility.  If it is true that in addition to its role 
in the clearance of lipoproteins, apoE also functions as a signaling molecule for various metabolic 
pathways, then the concentrations and availability of apoE in the plasma and extracellular spaces 
as well as its binding preference to various receptors could be critical regulators of the signaling 
process.  An important potential modifier of apoE availibity is the LDLR.  Which raises another 
important question:  Is the E4 effect dependent on the LDLR?  Increasing LDLR expression using 
the models described in Chapter 3 suggested that the answer to this question is “yes”.  There I 
showed that, within the experimental range, raising LDLR expression had detrimental effects 
specific to apoE4, but not apoE3.  However, the data presented in Chapter 2 suggests the opposite 
– that the apoE4 effect can indeed occur in the absence of the LDLR.  Taken together, this implies 
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that the dyslipidemic E4 effect is either a completely receptor independent effect or is a recepotor-
mediated effect that can be governed by other members of the LDLR family (LRP, VLDLR, etc.).   
           As diabetes reaches epidemic proportions across the world, millions of people will face 
dramatically increased risk of developing cardiovascular disease (18-19).  Diabetic dyslipidemia 
stands out as a potential cause of this increased risk of diabetic patients.  I have shown here that 
ApoE, an important mediator of normal lipoprotein metabolism and atherosclerosis, plays a role in 
modulating diabetic dyslipidemia and diabetic atherosclerosis as well.  Already at an increased risk 
of developing CVD, approximately 60 million Americans carrying the E4 allele may experience 
more severe diabetic dyslipidemia due to an E4 specific shift in metabolic homeostasis.  Taken 
together, the studies described here suggest a mechanism by which ApoE modulates both glucose 
and lipid metabolism during diabetes, thereby effecting the progression of atherosclerosis.   In the 
metabolic processes of glucose and lipoprotein regulation, and specifically in diabetic dyslipidemia 
where the two substantially overlap, the role of ApoE has broad and significant implications for a 
wide spectrum of disease states.   
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6.1 Summary 
 
The objective of this study is to examine the effects of apoB100 structure, specifically a 
mutation in the LDLr binding region, on the production of LDL and development of 
atherosclerosis in vivo.  Ldlr–/–Apobec1–/– mice lacking the LDLR and apoB editing enzyme 
accumulated LDL in plasma and developed severe atherosclerosis when they had wild-type 
apoB100. In marked contrast, in Ldlr–/–Apobec1–/– mice carrying the Apob100-β mutation, in the 
2 putative LDLR-binding domains of apoB prevented both LDL accumulation and 
atherosclerosis. Intestinal absorption of lipids and triglyceride secretion from the liver were not 
affected. However, the VLDL particles with apoB100-β were larger in volume by about 70%, 
and carried approximately four times as much apoE per particle. ApoB100-β synthesis rate in the 
primary hepatocytes was normal, but its intracellular degradation was enhanced. Additionally, 
mutant apoB100 VLDL cleared from the circulation more quickly in vivo through apoE-LRP-
mediated mechanism than VLDL with wild-type apoB100. In contrast, uptake of the 2 VLDL by 
macrophages were not different.  
While conformational change to apoB100 during conversion of VLDL to LDL exposes 
LDLR binding domains and facilitates LDLR-mediated lipoprotein clearance, it may also inhibit 
LRP-mediated VLDL uptake and contribute to LDL accumulation in familial 
hypercholesterolemia.  Mice that lack the LDLR and ApoB editing enzyme (Ldlr–/– Apobec1–/–) 
accumulate LDL and develop severe atherosclerosis. Conversely, Ldlr–/– Apobec1–/– mice 
carrying Apob100-β with altered sequences in the putative LDLR-binding domains of apoB 
neither accumulate LDL nor develop atherosclerosis. This finding highlights a potential 
therapeutic target for patients with familial hypercholesterolemia. 
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6.2 Introduction 
 
Apolipoprotein (apo) B is an essential component of VLDL, LDL, and chylomicrons. ApoB 
normally exists in 2 forms, apoB100 and apoB48; both are the products of the same gene.  
ApoB100 comprises 4536 amino acids, synthesized in the liver, and secreted into the circulation 
as a structural component of VLDL.  ApoB48 is 48% of full-length apoB, and is formed as a 
result of posttranslational editing of ApoB mRNA by the apoB editing complex (apoBEC), which 
changes Gln at codon 2153 to a stop codon (1).   ApoB48 is synthesized in the small intestine 
and is required for the packaging of lipids into chylomicrons.  Whereas human liver makes 
exclusively apoB100, a large proportion of message in the mouse liver is edited and consequently 
mice produce both apoB48 and apoB100 from the liver (2). 
In addition to maintaining the structural integrity of lipoprotein particles, apoB100 also 
functions as a ligand for the LDLR and is therefore a primary determinant of circulating LDL 
cholesterol levels.  The LDLR-binding domain of apoB100 has not been fully defined; however, 
biochemical, immunochemical, and genetic evidence suggests that it is a region of net positive 
change located in the carboxyl-terminal portion of apoB100.  Two sequences, residues 3147 to 
3157 and 3359 to 3367, are enriched in basic amino acid residues and have been proposed as 
putative LDLR-binding domains in both species (3).  The sequence at 3359 to 3367 is highly 
conserved among mammalian species and is also similar to the LDLR-binding site of apoE.  
Also, Boren et al showed that the removal of positive charges from residues 3359 to 3367 by 
site-directed mutagenesis renders the LDL containing the modified apoB defective in LDLR 
binding (3).  
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            To define the regions of apoB that bind the LDLR, we previously introduced mutations 
into the mouse Apob gene (4).  The apoB100-β protein is the same length as apoB100 but 
contains 2 peptide sequences for human β-globin in place of the residues 3147 to 3157 and 3359 
to 3367.  The modification also drastically reduced the net positive charges and amphipathic 
helicies of the 2 domains.  We expected that the mice producing apoB100-β would model 
defective apolipoprotein B100 in humans by accumulating binding-defective LDL in plasma (5).  
However, we found that the apoB100-β/B100-β mice have slightly, but not significantly lower than 
normal, total plasma cholesterol and HDL cholesterol, and the amount of plasma LDL was not 
different from that in wild-type mice (4).  One explanation is that these 2 regions are not essential 
for apoB100 binding to the LDLR in vivo. The interpretation, however, is complicated because 
mice normally have very little apoB100-containing LDL particles in circulation. In addition, the 
production of apoB48 from the liver and the efficient clearance of apoB48-containing remnants 
mediated by apoE make the metabolism of apoB100 difficult to study in vivo in mice.  
            The present study examined the effect of apoB100-β-containing LDL by introducing the 
mutation onto a background of Ldlr–/–Apobec1–/– double mutants; a model of human familial 
hypercholesterolemia with severe atherosclerosis. Apobec1–/– mice that lack the mRNA editing 
enzyme produce only apoB100 (7), whereas Ldlr–/– mice that lack LDLR accumulate LDL 
cholesterol in plasma (6, 7).  Surprisingly, when these mice also carry the apoB100-β mutation, 
they are completely protected from hypercholesterolemia and atherosclerosis that normally 
occurs in Ldlr–/–Apobec1–/–mice.    
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6.3 Methods 
 
Animals and Diets 
            The apoB100-β allele codes for "VHLTPVEKSAVT" and "KEFTPPVQAAYQ" instead 
of "LSVKAQYKKNSD" and "GTSRLMRKRGLK" of the wild-type apoB100 allele at residues 
3143 to 3154 and 3356 to 3366, respectively.4  Ldlr–/– mice (B6;129S7-Ldlrtm1Her/J) were obtained 
from the Jackson Laboratory. Apobec1–/– mice were obtained from Dr Eddy Rubin at the 
Lawrence Berkeley National Laboratory (7).  Three strains of mutants were crossed to generate 
mice that are heterozygous for the Apob locus and doubly homozygous for the Apobec1 and the 
Ldlr loci.  These mice were then crossbred, and Ldlr–/–Apobec1–/– mice with Apob genotypes of 
100/100 (wild type), 100/100-β (heterozygous), and100-β/100-β (homozygous) were generated 
for experiments.  Their genetic backgrounds were complex mixes between C57BL/6J, 129/SvEv, 
and129/Ola. Animals were maintained on normal chow (NC; 4.5% fat, 0.022% cholesterol; 
Prolab Isopro 3000; Agway Inc), or were fed a high-fat Western-type diet (HFW; 21% fat, 0.2% 
cholesterol; TD 88137; Harlan Teklad).  Mice in all experiments were age-matched within 3 
weeks. All procedures for the handling of mice were approved by the Institutional Animal Care 
and Use Committee of the University of North Carolina at Chapel Hill.  
 
Biochemical Analyses and Atherosclerosis Evaluation 
            Mice were fasted 4 hours before analysis. Liver and fecal lipids were extracted with 
chloroform/methanol.8  Plasma lipids, lipoprotein distribution, and triglyceride secretion rate, 
were determined as described (9).  Lipoprotein particle diameters were determined by dynamic 
light scattering analysis using a Microtrac 250 (10).  Peritoneal macrophages and hepatocytes 
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were isolated as described (11, 12).  The VLDL (d <1.006 g/mL) and LDL (d=1.06 to 1.10 g/mL) 
fraction was isolated from pooled plasma by ultracentrifugation and labeled with 1,1'-
dioctadecyl-3,3,3',3'- tetramethylindocarbocyanine perchlorate (DiI C18; Molecular Probes Inc) 
(13), or with 125I (Iodine-125 Radionuclide, Perkin Elmer) (14), for clearance assays.  Fibroblasts 
were kindly provided by Dr J. Herz at the University of Texas Southwestern Medical Center. 
Cellular lipids were extracted with isopropanol and measured with a microscope fluoromete r 
(13).  Gene expression in the liver was analyzed by real-time polymerase chain reaction (PCR), 
and quantification of atherosclerosis was carried out as described (11).  
 
Data Analysis 
            Values are reported as mean±SEM unless otherwise stated. Data were analyzed by 
ANOVA using JMP software (SAS Inc). 
 
 
6.4 Results 
 
ApoB100-β causes marked reduction of LDL in Ldlr-/-Apobec1-/- mice.   
Ldlr-/-Apobec1-/- mice with wild type apoB100 had high levels of plasma cholesterol and 
triglycerides on NC, and further increased plasma lipids on a HFW diet (Table 6.1).  In contrast, 
both plasma cholesterol levels in the Ldlr-/-Apobec1-/- mice that are heterozygous and homozygous 
for the apoB100-β mutation were reduced in an allele dose-dependent manner.  The protective 
effect of the apoB100-β mutation compared to controls was retained when mice were fed a HFW 
diet, although plasma cholesterol levels increased about 3 fold in all mice.  Plasma levels of 
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triglyceride, free cholesterol and phospholipids in mice with apoB100-β were also significantly 
lower than those with apoB100 mice.   
When plasma lipoproteins from male mice on normal chow diet were analyzed by fast 
protein liquid chromatography (FPLC), over 60% of the plasma cholesterol was in the LDL 
fraction in Ldlr-/-Apobec1-/- mice with wild type apoB100.  In contrast, a striking absence of LDL-
cholesterol was noted in the plasma of Ldlr-/-Apobec1-/- mice homozygous for apoB100-β (Figure 
6.1A).  Mice with one copy of apoB100-β had approximately half the amount of LDL as those 
with wild type apoB100.  All mice had very low levels of VLDL cholesterol, and there was no 
difference in the amount of HDL. The possession of apoB100-β resulted in a similar reduction of 
triglycerides in the LDL fraction (Figure 6.1B).  SDS gel electrophoresis of lipoprotein fractions 
from plasma of mice fed a HFW diet showed that the distribution of apoB100-β among various 
classes of lipoproteins was similar to that of normal apoB100 with the highest concentration in the 
LDL range (1.02 g/ml>d>1.04 g/ml, Figure 6.1C).  However, total apoB100-β in these mice was 
much less than wild type apoB100, since samples of three times of apoB100-β plasma volume was 
loaded compared to apoB100 plasma.  Total plasma apoE was also less in mice with apoB100-β 
than in mice with apoB100, but the ratio of apoE/apoB on the lipoprotein particles in the apoB100-
β mice was about four times higher than in apoB100 mice.  
While there was no difference in adipose tissue weight, the liver weight per body weight 
was slightly but significantly smaller in mice with apoB100-β (P<0.005, Figure 6.1D). Hepatic 
intracellular cholesterol pools in the two groups of mice were not significantly different after 2 
months on HFW diet.  In contrast, the liver triglyceride content of Ldlr-/-Apobec1-/- males with 
apoB100-β was significantly lower than in mice with wild type apoB100 (P<0.001, Figure 6.1E).  
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Fecal cholesterol and triglyceride levels of mice after 2 months on HFW diet were not significantly 
different (Figure 6.1F). These data suggest that the apoB100-β mice are also protected from liver 
steatosis.  Under light microscopy, however, liver sections from mice on HFW contained similar 
degrees of fatty droplets and no remarkable difference was observed between the Apob genotypes 
(data not shown).  
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Apob 
genotype 
      Normal Chow Diet High Fat Western Diet 
 
TC (mg/dl) TG (mg/dl) TC    (mg/dl) TG (mg/dl) FC   (mg/dl) PL   (mg/dl) 
♀ 
100/100 380±31(15) 78±6 (15) 1,005±35 (24) 134±14 (20) 253±37 (15) 627±23 (10) 
100/100-β 196±7 (10) 36±3 (10) 476±82 (6) 124±56 (6) 143±36 (10) 342±21 (10) 
100-β/100-β 93±6 (15) 23±3 (15) 292±24 (19) 60±5 (15) 84±14  (8) 236±8  (8) 
♂ 
100/100 478±23 (7) 99±7 (7) 1,161±26 (11) 599±22 (11) n.d. n.d. 
100/100-β 256±10 (8) 60±9   (8) n.d. n.d. n.d. n.d. 
100-β/100-β 126±7 (8) 39±4   (8) 329±20 (7) 149±29 (7) n.d. n.d. 
 
 
 
 
 
Table 6.1. Plasma lipids in Ldlr-/-Apobec1-/- mice with wild type apoB100 or apoB100-β  mutation.  Data 
are mean±S.E. in mg/dl.  Plasma samples were collected from mice after a 4 hr fast.  The numbers in parentheses 
are the number of animals. F, females; M, males; TC, total cholesterol; TG, triglycerides; FC, free cholesterol; 
PL, phospholipids. n.d., not determined.  Effects of Apob genotypes are highly significant in all categories 
(P<0.0001) 
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Figure 6.1. Plasma and tissue lipids.  Plasma lipoprotein distribution by FPLC (A) cholesterol, (B) 
triglycerides. (C) SDS-PAGE of apoB100, apoB-100β, and apoE in VLDL to LDL (1.006 – 1.06 g/ml) 
density fractions.  Samples equivalent to 5 µl of apoB100 plasma and 15 µl of apoB100-β plasma were 
loaded. M, weight markers.  (D) Tissue weight normalized to body weight, (E) liver lipid contents and (F) 
fecal lipids. Number of animals is in each bar. Error represents SEM. *, P<0.005, **, P<0.001.        
  
  155 
Ldlr-/-Apobec1-/- mice with apoB100-β secrete larger VLDL  
A possible source of the disparity in plasma LDL levels is a difference in hepatic VLDL 
production rates.  To estimate the secretion rate of triglyceride-rich lipoprotein (TRL) particles from 
the liver, we injected Triton WR1339 (Tyloxapol) intravenously into mice to inhibit lipolysis and 
uptake of TRLs, and measured plasma triglycerides (Figure 6.2A).  Although the basal triglyceride 
levels differ in the two groups of mice, triglyceride secretion rates were nearly identical at 280-300 
µg/ml/hr regardless of whether they have apoB100 or apoB100-β.  
We next analyzed VLDL particle size at 2hr post-Tyloxapol injection.  The size of particles 
in the  <1.006 g/ml density fraction was significantly different between the two groups of Ldlr-/-
Apobec1-/- mice; the mean±SD diameter of apoB100-β VLDL particles were larger (55.0±15 nm) 
than those with wild type apoB100 (45.6±14 nm).  Based on the difference in the diameter, we 
estimate that the average apoB100-β VLDL has approximately 46% more surface area and 76% 
greater volume than that of the normal apoB100 VLDL.  Assuming that the triglyceride content of a 
particle is relative to its volume, this implies that the number of VLDL particles secreted from the 
Ldlr-/-Apobec1-/- liver with apoB100-β is approximately 60% that from the liver with wild type 
apoB100.  
To examine the production and degradation of apoB100 proteins, we conducted a pulse-
chase experiment with radiolabelled methionine in the primary hepatocytes isolated from the Ldlr-/-
Apobec1-/- mice with apoB100 and with apoB100-β (Figure 6.2B).  Immunoprecipitable apoB 
protein in the apoB100-β cells after the 30-minute-pulse was not significantly different from that in 
apoB100 cells, suggesting that the initial synthesis rates are not different. After 4hr chase in the 
medium with excess of cold methionine, however, the immunoprecipitable apoB protein both in the 
medium and associated with cells was significantly less in the apoB100-β hepatocytes.  Thus, the 
  156 
mutated apoB protein is degraded more quickly, leading to the reduced number of VLDL particles 
secreted from the Ldlr-/-Apobec1-/- liver with apoB100-β.  
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Figure 6.2. Hepatic TG secretion and hepatocyte apoB metabolism. (A) Hepatic triglyceride secretion 
rates.  Female mice (5-8 month old fed a HFW, n=11) were injected via tail-vein with Triton WR-1339 and 
plasma triglyceride levels were measured post-injection. (B) 35S Pulse-chase analysis in primary 
hepatocytes. ApoB100 bands in the Gel were quantified using Image J software. Error represents SEM. *, 
P<0.005, **, P<0.001. 
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B100-β VLDL is efficiently cleared from the circulation 
The lack of LDL accumulation in the Ldlr-/-Apobec1-/- mice with apoB100-β is not 
proportional to the amount of VLDL particles secreted in these mice compared to that in mice with 
wild type apoB.  To test a hypothesis that apoB100-β VLDLs are cleared more efficiently thn 
apoB100 VLDL, we isolated VLDL from Ldlr-/-Apobec1-/- mice with either apoB100 or apoB100β, 
labeled them with 125I, and injected them into Ldlr-/- mice via the tail vein.  Monitoring plasma 
clearance of 125I labeled VLDL over a 2 hour period showed that 125I VLDL with apoB100-β are 
cleared faster than VLDL with wild type apoB100 (Figure 6.3A).  To determine the specific tissue 
loci of the cleared VLDL, we repeated the 125I-VLDL turnover, this time measuring radioactivity 
in various tissues after 20 minutes. Of 125I-VLDL cleared, the majority was found in the liver. The 
distribution of 125I-VLDL with apoB100β did not differ from that of 125I-VLDL with apoB100 in 
the five organs measured (Figure 6.3B). 
In order to assess the conversion of VLDL to smaller particles in vivo, plasma samples 
were isolated from mice two hours after 125I-VLDL injection, pooled, and separated into VLDL, 
IDL, and LDL fractions using ultracentrifugation.  Proportions of counts in the density fractions 
containing each class of lipoproteins were similar between mice received 125I-VLDL with apoB100 
and those with apoB100-β (Figure 6.3C).  Furthermore, the apoB100-β VLDL particles incubated 
with post-heparin plasma released FFA at rates of 12±1 nmol FFA/min compared to apoB100 
VLDL at 11±1 nmol FFA/min (Figure 6.3D), suggesting that the lack of putative LDLR binding 
domain sequences of apoB does not affect the lipolysis of VLDL in Ldlr-/-Apobec1-/- apoB100-β 
mice.   
Taken together, these experiments suggests that the absence of hyperlipidemia in LDLR-
deficient mice having apoB100 without the putative receptor-binding sequences is likely because 
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their VLDL particles are quickly cleared from the circulation before they become small, 
cholesterol-enriched LDL particles. 
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Figure 6.3. Lipoprotein clearance and lipolysis. (A) Clearance of 125I labeled apoB100 or B100-β VLDL 
in Ldlr-/-Apobec1-/- mice.  n > 3 for each group. (B) Organ uptake expressed as the percentage of total 125I-
VLDL in all organs measured. n = 3 for each group.  (C) Conversion of injected 125I-VLDL after 2hrs, 
expressed as a percentage of injected VLDL.  (D) FFA release in heparin treated plasma from Ldlr-/-
Apobec1-/- mice with apoB100 or apoB100-β measured over 1 hour.        
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Role of apoE-LRP mediated clearance  
To examine the specific roles of the LRP on apoB100-β particle uptake, we measured 
uptake of DiI labeled VLDL and LDL in mouse fibroblasts deficient in either LDLR (LDLR-/-
LRP+/+), in LRP (LDLR+/+LRP-/-), or in both LDLR and LRP (LDLR-/-LRP-/-, negative control 
cells).  Two hours after DiI-labeled apoB100-LDL was added to the medium, the uptake into 
LDLR+/+LRP-/- cells was significantly higher than in LDLR-/-LRP-/- negative control cells 
(Figure 6.4A).  The uptake of apoB100-LDL by the LDLR-/-LRP+/+ cells was also higher than in 
negative control cells.  Uptake of apoB100-β LDL was not increased by the expression of either 
LDLR or LRP.  The opposite pattern of uptake was observed in studies with VLDL.  In 30 min, 
DiI-labeled apoB100-β-VLDL was efficiently taken up by cells expressing LDLR, and particularly 
LRP, while no such increase over the uptake by negative control cells was found in cells given DiI-
labeled-apoB100 VLDL (Figure 6.4B). 
We next blocked hepatic LRP function using Ad-RAP to determine the role of the LRP in 
the clearance of apoB100-β VLDL in vivo.  While basal cholesterol and triglyceride levels in 
plasma are significantly lower in Ldlr-/-Apobec1-/- mice with apoB100-β than those with normal 
apoB100, the levels five days after Ad-RAP injection were not different between the two groups of 
mice.  FPLC analyses showed a similar accumulation of cholesterol in the VLDL fraction after 5 
days in both groups (Figure 6.5). These data imply that apoB100-β VLDL is removed by receptors 
inhibited by RAP, such as LRP.  We also examined the contribution of HSPG binding by 
incubating LDLR-/-LRP-/- cells at 4º C with Dii-VLDL. The amount of VLDL released from the 
surface by heparinase after 2h was not significantly different (Figure 6.6), suggesting that 
apoB100-β does not affect the binding ability of VLDL to proteoglycans. 
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To gain further insight into the apparent enhancement of lipoprotein clearance in Ldlr-/-
Apobec-/- mice with apoB100-β, we analyzed the expression of the Apob, Apoe and Lrp1 genes in 
the liver by real-time PCR.  While there was no Apob genotype effect on the mRNA levels for 
Apob and Lrp1, liver expression of Apoe was approximately twice as high in mice with apoB100-β 
as in mice with wild type apoB100 (Figure 6.7).  These data, combined with the higher apoE:apoB 
protein ratio, suggest that the increased production of apoE protein may be contributing to the 
accelerated clearance of apoB100-β containing VLDL-remnants and the resistance to 
hyperlipidemia in the apoB100-β mice even in the absence of LDLR. 
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Figure 6.4.  Uptake by fibroblasts of DiI-labeled lipoproteins with apoB100 or apoB100-β. (A) 
Cells were incubated with DiI-labeled LDL 37˚ C for 2 hr or (B) VLDL for 30 min. Error 
represents SEM.  *P<0.05, **P<0.005 against uptake in LDLR- LRP cells.  #, P< 0.05 between 
genotypes within the same cell system. 
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Figure 6.5. VLDL and LDL cholesterol distribution after RAP mediated blocking of LRP. 
Total plasma cholesterol (A) and triglyceride (B) at 0 and 5 days after injection of adRAP. White 
bars and black bars indicate Ldlr-/-Apobec-/- mice with wild type apoB100 and those with apoB100-
β, respectively. The distribution of plasma VLDL and LDL cholesterol in Ldlr-/-Apobec-/- mice 
with wild type apoB100 (C) and in those with apoB100-β (D).  Blood samples were collected from 
mice after a 4 hr fast prior (filled symbols) and at 5 days after injection of adRAP (open symbols). 
A total of 50 µl plasma, pooled from groups of 3 male mice, was size-fractionated by FPLC and 
cholesterol amount in each fraction was measured.  ** denotes P<0.005 between mice with 
apoB100 and mice with apoB100-β. 
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Figure 6.6.  Heparinase releasable VLDL.  Dii-VLDL released by LDLR-/-LRP-/- fibroblasts 
after treatment with heparinase.  Cells were incubated at 4˚ C for 2 hr with Dii-VLDL. VLDL was 
isolated from Ldlr-/-Apobec1-/- mice homozygous for apoB100 or apoB100-β. 
 
 
  166 
 
 
Figure 6.7.  Hepatic Apoe, Apob and Lrp1 gene expression.  Liver tissues were isolated from 6-8 
month old mice fed a HFW diet for 1-2 months.  mRNA amounts are normalized to β-actin and 
expressed relative to the mean of B100/B100 mice as 100%. Error represents SEM. The number of 
animals is shown inside each bar. * P<0.002. 
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Ldlr-/-Apobec1-/- mice with apoB100-β are protected from development of atherosclerosis            
   High levels of LDL are a well-documented risk factor for atherosclerosis.  Ldlr-/-Apobec-/- female 
mice with apoB100 had a significant size of lesions (34±6 x103µm2), even when they were on NC 
diet and were as young as 4-5 months old (Figure 2.8A).  In marked contrast, the apoB100-β 
mutation demonstrated a significant athero-protective effect.  While three out of five Ldlr-/-Apobec-
/-
 mice heterozygous for apoB100-β had visible plaques (16±7 x103µm2), there were absolutely no 
plaques seen in mice homozygous for the apoB100-β mutation.  The overall effect of the Apob 
genotype on plaque development was P<0.002 by ANOVA.   Feeding a HFW diet for 2 months 
accelerated the plaque development in the Ldlr-/-Apobec-/- mice with apoB100 (mean lesions size 
54±8 x103µm2; n=5).  In contrast, there were virtually no lesions present in apoB100-β mice but 
only very small foam cell aggregations (1.7±0.8 x103µm2, P<0.002).   
To examine whether direct VLDL scavenging by macrophages rather than LDL 
accumulation is responsible for the dramatic differences in atherosclerosis, we isolated peritoneal 
macrophages from Ldlr-/- mice and incubated with equal amounts of DiI-labeled VLDL in the 
medium.  Uptake of the DiI-VLDL with apoB100 by the macrophages was a little more enhanced 
compared to that with apoB100-β, but the differences were not statistically significant (Figure 
6.8B).   A similar result was obtained in the macrophages isolated from wild type mice (data not 
shown), indicating that the scavenging by macrophages of the VLDL is not affected by the 
apoB100-β mutation. 
Taken together our data demonstrate that, even in the absence of LDLR, a mutation in the 
putative receptor binding domains of apoB prevents LDL accumulation, and dramatically reduces 
atherosclerosis. 
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Figure 6.8.  Atheroslcerosis and macrophage VLDL uptake. (A) Atherosclerotic plaque sizes at 
the aortic roots of 4 month old female Ldlr-/-Apobec1-/- mice. Number of animals is in parentheses. 
(B) Macrophage VLDL uptake. Ldlr-/-Apobec1-/- macrophages were incubated with DiI-labeled 
VLDL with apoB100 or with apoB100-β. Cellular florescence is expressed as Arbitrary Units 
(AU) per cell gram of cell protein.        
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6.5 Discussion 
 
            LDL is generated in the circulation from VLDL produced by the liver following lipolysis 
and exchange of surface apolipoproteins.  During this conversion, conformational changes occur in 
its structural protein, apoB100, allowing for the exposure of domain(s) that interact with LDLR 
(15-17).   Exposure of the receptor binding domain and subsequent binding of apoB100 to the 
LDLR is the major pathway for the clearance of LDL cholesterol by the liver, as illustrated by the 
marked accumulation of LDL in plasma of patients and in animals lacking LDLR (18-21).  
Particles that lack full length apoB, such as apoB48-containing chylomicron remnants, can acquire 
apoE which mediates efficient clearance of these particles by the LDLR, LRP and other receptors 
which may act in concert with proteoglycans (22).            
            To investigate the mechanisms for the uptake of apoB48- and apoB100-containing 
lipoproteins by the LDLR and by the LRP, Veniant et al previously characterized plasma 
lipoproteins in the Ldlr-/- mice homozygous for an “apoB48-only” allele or homozygous for an 
“apoB100-only” allele (24).  The authors concluded that the LDLR plays a significant role in the 
clearance of both apoB100 and apoB48 containing lipoproteins, and that the LRP is important for 
apoB48-containing lipoproteins but has little if any capacity to remove apoB100-containing 
lipoproteins from the plasma.  The “apoB100-only” Ldlr-/- mice are phenotypically identical to the 
Ldlr-/-Apobec1-/- mice with wild type apoB100 we used in the current study.  Interestingly, the 
plasma lipids and lipoprotein distribution in Ldlr-/-Apobec1-/- mice with mutant apoB100-β are very 
similar to “apoB48-only” Ldlr-/- mice, despite that apoB100-β retains the full length of the apoB 
protein.  Both strains of mice have no substantial accumulation of LDL particles, suggesting that 
apoB100-β remnants, like apoB48-only remnants, are cleared via LRP in the absence of LDLR and 
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that the length of apoB protein does not influence this process.  However, while Veniant et al 
showed that LRP inhibition with RAP of “apoB48-only” Ldlr-/- mice leads to higher VLDL levels 
than in “apo-B100-only” Ldlr-/- mice (23), VLDL accumulation in the Ldlr-/-Apobec1-/- mice with 
apoB100 and those with apoB100-β were similar after LRP inhibition, suggesting that additional 
mechanisms may present in the protective effects noted in the apoB100-β producing mice.   
The Ldlr-/-Apobec1-/- mice with apoB100-β do not accumulate substantial LDL particles in 
plasma even when fed a HFW diet.  This lack of LDL accumulation occurs despite the inability of 
apoB100-β-containing LDL to be cleared in vitro.  Importantly, the livers of Ldlr-/-Apobec1-/- mice 
with apoB100-β appear to produce a smaller number of larger VLDL particles than the livers of 
the Ldlr-/-Apobec1-/- mice with apoB100, despite equal expression of the Apob gene and protein 
synthesis.  However, the reduction of LDL cholesterol in the Ldlr-/-Apobec1-/- mice with apoB100-
β is more than the reduction of apoB secreted.  This is in contrast to the report by Crooke et al. that 
Ldlr-/- mice treated with an apoB antisense oligonucleotides had a reduction of apoB mRNA by 
74% but still had 48% levels of LDL-cholesterol compared to the pretreatment levels (24).  It has 
long been recognized that the larger VLDL particles are removed faster and less likely converted to 
LDL than smaller VLDL, and a larger surface area of apoB100-β VLDL may allow more apoE to 
associate with the particle and facilitate LRP mediated uptake (25, 26).  Ldlr-/-Apobec1-/- mice with 
apoB100-β have plasma lipoproteins containing four-fold higher apoE protein per particle, and two 
fold higher Apoe gene expression in the liver than mice with apoB100.  All together, these changes 
favor the enhanced clearance of apoB100-β containing particles via the LRP. 
We also observed an enhanced degradation of apoB100-β in primary hepatocytes from the 
Ldlr-/-Apobec1-/- mice with apoB-100β in culture. Whether the accelerated degradation of 
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apoB100-β results from its abnormal protein folding or is the consequence of enhanced turnover 
has yet to be determined. While a limited apoB protein available for lipoprotein assembly could 
account for the larger size of VLDL, a question remains as to whether apoB100-β fails to form 
subsets of VLDL particles that are pre-destined to form LDL particles.  Studies have demonstrated 
that a substantial amount of newly synthesized apoB protein is degraded rather than secreted, and 
that its interaction with LDLR channels apoB toward pre-secretory degradation (27-30).  Reuptake 
of newly synthesized lipoproteins by LDLR can also attenuate VLDL secretion, and both apoE and 
apoB are important for this process (31, 32).  Loss of these regulations results in an increased 
secretion of apoB proteins and smaller, underlipidated VLDL particles in humans and mice that 
lack functional LDLR (33). 
The metabolism of lipoproteins with apoB100-β mutation is consistent with other 
observations.  For example, truncations of apoB on the C-terminal side of amino acid 3500 result 
in more efficient clearance of VLDL (34).  Individuals heterozygous for a R3480P mutation in 
apoB exhibit hypobetalipoproteinemia because of a reduced conversion of VLDL to LDL, despite 
that this mutation caused reduced binding of LDL to the LDLR (35).  Similarly, milder than 
expected hyperlipidemia in individuals with familial defective apolipoprotein B-100 due to 
mutations at R3500 has been attributed to an enhanced removal of apoE-containing VLDL and 
decreased production of LDL (36, 37).  The apoB100-β mutation may also affect a process of 
structural/conformational change of apoB100 that is important for the in vivo generation of LDL 
particles as well as for LDLR binding, although interpretation is complex because amino acid 
changes disrupting amphipathic helices represented by sites A and B likely cause additional 
conformational changes of apoB on LDL and VLDL.  Systematic replacements of the basic LDLR 
binding sequences with acidic or neutral residues would provide a potentially less disruptive and 
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comprehensive approach.  Chatterton et al. hypothesized that the apoB100 “bow”, where a 
segment of apoB100 crosses over itself between amino acid residues 3000 and 3500, inhibits 
interaction of apoB100 protein with LDLR, hence inhibiting clearance (38).   Since the apoB100-β 
mutation at amino acids 3147-3157 and 3359-3367 are within the proposed bow crossing structure, 
a mutation in these sequences may physically block or otherwise disrupt “bow” structure 
formation.   
There is little doubt that the exposure of the positively charged domains of apoB100 to the 
lipoprotein surface following conformational changes is required for the effective clearance of 
LDL through LDLR.  Considering the overall consequences of the mutations in the second half of 
the apoB100, however, it is tempting to speculate that the exposure of the positively charged 
domains of apoB100 may also inhibit the accumulation of apoE on the particles required for their 
apoE-mediated uptake via LDLR and/or LRP.  This is consistent with the hypothesis raised by 
Veniant et al that the presence of the carboxyl half of apoB100 (amino acids 2153-4536) on the 
surface of the lipoprotein prevents the lipoprotein particle from binding a “sufficient dose of 
supplemental apoE” that is necessary for the lipoprotein particle to escape circulation via uptake by 
the LRP (23).   Lack of the putative LDLR binding domains in apoB100-β may also prevent the 
secretion of newly packaged but underlipidated particles by enhancing the degradation of apoB 
through enhanced interactions between apoE and LDLR/LRP. 
In conclusion, we have demonstrated that the mutation in the LDLR binding domains of 
apoB100 dramatically protects mice from both hypercholesterolemia and atherosclerosis that 
develop in the absence of LDLR.  Our observations raise an intriguing possibility that an 
interference of the exposure of the putative LDLR-binding domains to the lipoprotein surface may 
indeed enhance remnant clearance through apoE-mediated mechanisms.  This may be applicable as 
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a potential therapeutic approach for preventing LDL accumulation in patients with familial 
hypercholesterolemia. 
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